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PDGF   platelet-derived growth factor 
PFA   paraformaldehyde 
PLP   proteolipid protein 
PPMS   primary progressive MS 
rMOG   recombinant myelin oligodendrocyte glycoprotein 
RMS   rostral migratory pathway 
RRMS   relapsing-remitting MS 
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VLA-4   very late antigen-4 (integrin alpha4beta1) 





Remyelination represents an important self repair mechanism in demyelinating diseases 
such as multiple sclerosis (MS). The intrinsic regenerative potential of the cerebral cortex 
is considerable, however cortical MS lesions frequently fail to remyelinate, especially at 
later stages of the disease. Repeated demyelinating events are one assumed cause of 
remyelination failure and the subject of this work. 
The aim of the study was to determine whether repetitive demyelinating episodes may 
exhaust the intrinsic cortical remyelinating capacity. Therefore, MS-like lesions were 
induced in the rat targeted cortical experimental autoimmune encephalomyelitis (EAE) 
model in a repeated manner. After subcutaneous immunization with recombinant rat 
myelin oligodendrocyte glycoprotein (rMOG), a cytokine cocktail composed of the 
proinflammatory cytokines tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) was 
stereotactically injected in the rat cerebral cortex thereby leading to focal inflammatory 
demyelinating lesions. Lesions were repetitively induced at intervals of three weeks, 
simulating the repetitive events in relapsing-remitting MS. 
Histological analysis revealed widespread subpial and intracortical demyelinated lesions 
within the injected cortical hemisphere 3 days after lesion induction. Demyelination was 
accompanied by loss of mature oligodendrocytes and activation/recruitment of 
macrophages/microglia at this time point. However, three weeks after lesion induction 
extensive remyelination, restoration of oligodendrocyte population and resolution of 
inflammation was observed. This picture of de- and remyelination was consistently 
observed even after four cycles of demyelination at the same anatomical area. Although 
the fraction of myelinated axons was extensively restored after repetitive lesioning it did 
not fully recover. The initial inflammatory response measured by the density of activated 
macrophages/microglia was markedly stronger compared to the subsequent episodes. In 
contrast to NogoA-positive cells, oligodendrocyte transcription factor 2 (olig2)-positive 
oligodendrocyte precursor cell (OPC) density was stable and even increased at particular 
time points. Proliferation of olig2 and NogoA-positive cell populations was observed 








identified within remyelinated lesions, in contrast to substantial proliferation of olig2-
positive OPCs.  
This work demonstrates the extensive intrinsic regenerative capacity of the rat cerebral 
cortex after repeated demyelinating insults. Four cycles of cortical demyelinating 
episodes did not lead to reduction of the cortical remyelinating capacity in our 
experimental setting. Our results suggest furthermore that oligodendroglial recruitment 
occurs by differentiation of existing rather than newly generated OPCs within the 
cerebral cortex. Findings from these studies will contribute to understanding the 




MS also known as encephalomyelitis disseminata, is one of the most common 
neurological diseases in young adults. MS was first described by Jean Martin Charcot in 
1868 and is currently believed to be an autoimmune disorder causing inflammatory 
demyelination in the central nervous system (CNS). In northern Europe the general 
population prevalence of MS varies in average between 20-60/100000, being more 
common in females (Sospedra and Martin, 2005). 
As MS is a complex and heterogeneous disorder, many questions remain open despite 
intensive research. The main focus of this study addresses cortical pathology of MS 
which extent has been underestimated for a long time by the scientific community. This 
chapter provides an introduction to clinical and pathological features of multiple 
sclerosis, especially focussing on cortical grey matter pathology. In addition, 
remyelination, oligodendroglial recruitment and genesis will be addressed. Finally, the 
targeted cortical EAE model which is used for studying repetitive inflammatory 
demyelination will be introduced. 
 
1.1 Multiple Sclerosis 
1.1.1 Etiology of MS 
Despite extensive efforts the etiology of MS remains enigmatic. MS is considered to be 
autoimmune in nature, but its exact cause remains still unknown. However, it occurs to be 
a result of genetic and environmental factors (Sospedra and Martin, 2005; Gold et al., 
2006).  
Genetic predisposition seems to play a role since first-degree relatives and monozygotic 
twins of affected individuals show a higher risk to develop MS (Sospedra and Martin, 
2005). Furthermore, susceptible genes on chromosome 6p21 in the area of the major 
histocompatibility complex (MHC) seem to account for 10-60% of genetic risk in MS 





In addition to genetic factors, epidemidological studies strongly suggest that 
environmental factors are involved in disease predisposition. To these factors belong e.g. 
sunlight exposure and ultraviolet radiation, hormonal and hygienic status, as well as the 
consequences of socioeconomic and industrial development (Sospedra and Martin, 2005). 
Infectious agents have been furthermore postulated to cause MS. This is supported by 
studies showing a possible association between viral infections and exacerbations of MS 
symptoms (Bebbe et al., 1967; Sibley et al., 1985). Especially, the Epstein-Barr virus 
(EBV) has been related to MS but its direct implication in the disease remains unproven 
(Johnson, 1994; Bagert, 2009). 
 
1.1.2 Clinical presentation 
MS patients suffer from a variety of neurological symptoms, such as optic neuritis, 
sensory disturbances, weakness, diplodia, diminished dexterity, ataxia, fatigue and 
bladder dysfunction. Symptoms occur in either discrete attacks (relapsing forms) or 
slowly accumulating over time (progressive forms). The initial symptoms are often 
transient and mild, but worsen often with time ending with permanent disability. With 
regard to its clinical course, three main subtypes have been described (Lublin et al., 
1996):  
Relapsing-remitting MS (RRMS): 
The relapsing remitting subtype is the most frequent (85-90%) subtype of MS. It is 
characterized by relapses followed by remissions without any disease activity in between. 
Despite remission, disability may accumulate after each relapse. 
Primary progressive MS (PPMS): 
This subtype is characterized by progressive disability from onset of the disease, with no 
or occasional relapses and remissions. Approximately 10 to 15% percent of all MS 
patients show a primary progressive course. 





The secondary progressive subtype describes patients with initial relapsing-remitting MS, 
who then experience progressive disability with no definite remission. The conversion 
from the relapsing-remitting to the secondary progressive phase on average takes place 
between 15 and 20 years after disease onset. 
 
1.1.3 Immunology 
MS is considered to be caused by an autoimmune response against unknown antigens of 
the myelin sheaths. According to this concept, myelin antigens are recognized by 
professional antigen presenting cells (APCs) and presented in the periphery via MHC 
class II molecules to T helper 1 (Th1) cells. Following activation, priming and clonal 
expansion, CD4-positive cells infiltrate the CNS where they re-encounter their antigen. 
Upon restimulation by microglia, CD4-positive cells initiate effector functions such as 
the secretion of the pro-inflammatory cytokines TNF-α, IFN-γ and interleukin 2 (IL-2) 
(Merril, 1992). Thereby, attracted macrophages and resident microglia become activated, 
which in turn contribute to the inflammatory milieu by the release of matrix 
metalloproteinases (MMPs), oxyradicals and TNF-α. In addition, the secretion of the 
chemoattractants interferon-inducible protein-10 (IP-10) and Rantes and the activation of 
their respective receptors chemokine (C-X-C motif) receptor 3 (CXCR3) and chemokine 
(C-C motif) receptor 5 (CCR5), promote the recruitment of leukocytes into the sites of 
inflammation (Simpson et al., 1998; Martínez-Cáceres et al., 2002). CNS migration 
through the blood brain barrier (BBB) is enabled by the upregulation of the intercellular 
adhesion molecule-I (ICAM-I) and the vascular cell adhesion molecule-I (VCAM-I) on 
endothelial cells and their ligands leukocyte function-associated antigen-1 (LFA-1) and 
very late antigen-4 (VLA-4), the last ones being expressed on the surface of activated 
effector cells (Yusuf-Makagiansar et al., 2002). 
Class I MHC-restricted CD8-positive cells are supposed to play an important role in MS. 
They are considered to directly target oligodendrocytes and axons, indicated by secretion 
of cytotoxic granules and upregulation of cytotoxic T-cell markers such as Fas, Fas-
ligand and granzyme B (Lazzarini, 2004). B- and plasma-cells located in the meninges 





myelin-specific antibody responses in a subset of MS patients (Lucchinetti et al., 2000; 
Serafini et al., 2004). Antibodies may bind to membrane bound antigens enabling Fc-
receptor-mediated cytotoxicity and phagocytosis by activated macrophages. Furthermore, 
the complement cascade is initiated (Lazzarini, 2004). 
Inflammation usually resolves after each relapse and is promoted by a transition of CD4-
positive Th1 to Th2 cells. These lymphocytes secrete anti-inflammatory cytokines such 
as IL-4, IL5, IL-10, IL-13 and transforming growth factor-β (TGF-β), silencing the 
inflammatory reaction (Issazadeh et al., 1995). 
 
1.1.4 Histopathology 
MS is characterized by multifocal, demyelinated plaques with glial scar formation. T-cell 
infiltration occurs in all active MS lesions. However, histopathological heterogeneity was 
observed in MS lesions. Accordingly, four histopathological patterns were proposed 
(Lucchinetti et al., 2000). Pattern I describes a macrophage-associated demyelination 
promoted by toxic products such as TNF-α or reactive oxygen species (Probert et al., 
2000; Griot et al., 1990). In addition to macrophage activation, antibody and 
complement-mediated demyelination takes place in pattern II. Distal 
oligodendrogliopathy (pattern III) and primary oligodendrocyte degeneration (Pattern IV) 
was observed in a subgroup of patients (Lucchinetti et al., 2000).    
Importantly, these patterns describe the acute phase of disease in which inflammation and 
demyelination is still ongoing, and therefore termed “active” lesions. In contrast, chronic 
or inactive lesions, lacking signs of active demyelination, are characterized by 
demyelination, astrogliosis, axonal damage, and loss and can not be arranged to one of 
the four aforementioned patterns (Lazzarini, 2004).   
 
1.1.5 Cortical lesions 
Grey matter involvement in MS has already been observed in early disease history 
(Taylor, 1892; Sander, 1898; Brownel and Hughes, 1962). Later however, cortical lesions 





they were finally rediscovered by the end of the century (Kidd et al., 1999; Peterson et 
al., 2001; Bo et al., 2003). Since the use of sensitive in vivo imaging techniques, the 
importance of cortical involvement becomes more apparent (Filippi et al., 1996; Geurts et 
al., 2005; Kangarlu et al., 2007).   
Cortical demyelination is a frequent phenomenon occurring in 90% of MS patients with 
long disease duration (Albert et al., 2007). On average, between 10-25% of cortical grey 
matter is demyelinated (Albert et al., 2007; Bo et al., 2003; Kutzelnigg et al., 2005; 
Gilmore et al., 2009). In the progressive stage of the disease CNS grey matter is even 
more affected compared to white matter (Gilmore et al., 2009). Three main types of 
cortical lesions have been described, namely leukocortical lesions, which extend through 
white and grey matter, pure intracortical lesions and subpial lesions. Last mentioned 
lesion type is the most frequent and extensive one (Peterson et al., 2001; Bo et al., 2003).    
Compared to white matter lesions, cortical demyelination is less inflammatory, presenting 
with reduced lymphocyte infiltration and reduced microglia activation (Peterson et al., 
2001; Bo et al., 2003). Furthermore, complement deposition, limited astrogliosis and 
relative axonal preservation was reported (Schwab and McGeer, 2002; Peterson et al., 
2001; Wegner et al., 2006; Vercellino et al., 2005). Despite weak lymphocyte-mediated 
inflammation, follicle-like structures harbouring B-cells were observed in the sulcal 
meninges of SPMS patients. These structures are associated with enhanced axonal 
damage and disability (Serafini et al., 2004; Magliozzi et al., 2007). In addition to 
moderate axonal damage, neuronal loss and cortical atrophy was reported (Wegner et al., 
2006). On the contrary, reduction of synaptic densities does not necessarily occur 
(Vercelino et al., 2005; Kutzelnigg et al., 2007). However, reduced expression of amino 
acid transporters and gamma-aminobutyric acid (GABA) related transcripts, and 
enhanced excitotoxicity underline the functional consequences of cortical MS lesions 
(Vercellino et al., 2007; Dutta et al., 2006).  
Classically, MS patients present with sensory and motor symptoms. In case of cortical 
involvement patients may additionally suffer from cognitive and neuropsychiatric 
symptoms, thus contributing to disease severity already in early stages of the disease 






Remyelination is an important repair mechanism and is accompanied by functional 
recovery such as the reestablishment of salutatory conduction and the resolution of 
clinical symptoms (Smith et al., 1979; Jeffery et al., 1997; Merkler and Liebetanz, 2006). 
Remyelinated axons have thinner and shorter internodes and usually do not attain original 
dimensions (Blakemore, 1974; Ludwin and Maitland, 1984). In histological sections of 
MS patients, remyelinated areas are characterized by pale and less dense myelin, so 
called “shadow plaques” (Itoyama et al., 1980). Furthermore, remyelinated lesions can be 
detected by magnetic resonance imaging (Barkhof et al., 2003; Merkler et al., 2005).   
Remyelination is a frequent phenomenon, occurring in more than 50% of MS plaques 
(Lucchinetti et al., 1999; Patrikios et al., 2006, Patani et al., 2007). However, the grade of 
remyelination depends on anatomical location and disease stage (Stadelmann and Brück, 
2008; Goldschmidt et al., 2009). As an example, regions close to the ventrikel walls 
remyelinate less, opposed to those in the deep white matter (Patrikios et al., 2006). In 
turn, cortical grey matter remyelination is more frequent and extensive compared to white 
matter lesions (Albert et al., 2007). Despite long disease duration extensive remyelination 
can occur, but fails in the majority of cases at later stages of the disease (Patani et al., 
2007; Goldschmidt et al., 2009).     
Remyelination is neuroprotective, preventing secondary axonal damage (Kornek et al., 
2000; Irvine and Blakemore, 2008; Trapp and Nave, 2008). Furthermore, the presence of 
myelin proteins such as proteolipid protein (PLP) and 2’,3’-cyclic nucleotide 3’-
phosphodiesterase 1 (CNP1), plays an important role in axon stability (Lappe-Siefke et 
al., 2003; Griffiths et al., 1998; Edgar and Garbern, 2004).  
 
1.1.7 Mechanisms of remyelination 
Loss of remyelination capacity is considered to play an important role in MS pathology, 
however, the mechanisms causing impaired remyelination are not fully understood. To 
date there are three main hypotheses which describe the different possible causes of 





failure of recruitment hypothesis, in which inadequate provision of OPCs might be the 
cause of incomplete or total lack of myelin restoration. The second hypothesis describes 
how OPCs, after being recruited into the sites of demyelination fail to differentiate to 
remyelinating oligodendrocytes. Lastly, the dysregulation hypothesis suggests that 
remyelination might fail due to disturbances of the precise coordination of regenerative 
cellular events (Franklin and Kotter, 2008). Furthermore, disturbed axon-glia interactions 
may hinder remyelination (Franklin, 2002). Age is an aggravating factor for the efficacy 
of endogenous remyelination as shown in animal studies (Sim et al., 2002; Shen et al., 
2008). 
Treatments improving remyelination are not available yet. However, basic research in 
animal models proposes new approaches for future remyelination strategies. These 
include the enhancement of endogenous repair mechanisms such as the proliferation and 
differentiation of endogenous OPCs (Franklin and Kotter, 2008). Furthermore, successful 
transplantation of myelinating cells has been proven in several animal studies, but its 
therapeutic potential in humans remains open (Stangel und Trebst, 2006). The current 
standard therapy for MS consists of treatment with immunomodulatory drugs. These 
therapeutic approaches may indirectly influence remyelination by preventing further 
myelin damage (Lazzarini, 2004).  
 
1.2 Myelin 
1.2.1 Structure and function of myelin 
Neurons communicate by depolarizing the electrical potentials of their membranes, a 
process called action potential. This occurs by exchange of sodium and potassium along 
closely distributed channels on the axon. The majority of axons are wrapped by lipid-rich, 
lamellar structures named myelin sheaths. Due to the myelin-sheaths insulating 
properties, action potentials jump between myelin free spaces, a process called salutatory 
conduction. This provides fast and energy-efficient signaling over longer distances, 
allowing cross linking of remote brain areas. In the CNS myelin sheaths are built by 





to build multiple internodes on axons within their reaching area. Axons are accompanied 
by many oligodendrocytes, each of one myelinating a particular segment along the axonal 
route. In contrary, dendrites are never myelinated. Myelin sheaths are compact spiraled 
cellular processes that contain two plasma membranes and no cytoplasm.  Opposed to 
other cell membranes, myelin is composed of up to 75% of lipids. Furthermore, a variety 
of membrane proteins and cytoskeletal components are involved in formation and 
maintenance of this complex cell organelle. Briefly, the most abundant ones are PLP, the 
myelin basic protein (MBP), and the myelin associated glycoprotein (MAG). 
 
1.2.2 Myelin proteins 
PLP is the major integral membrane protein of myelin consisting of four transmembrane 
domains. It is distributed in compact myelin, and is important for structural stability of 
myelin, keeping normal spacing between single sheaths. Lack of PLP and its splice 
variant DM20 does not impair myelination but leads to structural disturbances followed 
by axonal damage in adulthood (Trapp and Nave, 2008).    
MBP is an extrinsic membrane protein located in the cytoplasmic leaflets of compact 
myelin. The MBP deficient shiverer mouse shows hypo- and dysmyelination, indicating 
an important role of this protein in myelin formation and preservation (Lazzarini, 2004).  
MAG is located in the periaxosomal and mesoaxonal membranes of compact myelin. 
This protein has been shown to participate in the control of compact myelin distribution 
and is essential for myelination and axonal integrity (Quarles, 2007).  
Myelin oligodendrocyte glycoprotein (MOG) is an integral membrane protein consisting 
of an immunoglobulin G (IgG)-like extracellular domain, a transmembrane domain, a 
membrane associated domain and two cytoplasmic domains. Quantitatively, it comprises 
of 0.05-0.1% of total myelin protein. However, it is of high immunological importance 
since it is an autoantigen frequently used to induce EAE. MOG is suggested to be a 
cellular adhesive molecule, regulating oligodendrocyte microtubule stability. Further, 
MOG might mediate interactions between myelin and the immune system, in particular 






1.3.1 Developmental oligodendrogenesis 
Neurons, astrocytes and oligodendrocytes are the most common cell types in the 
vertebrate CNS. Oligodendrocytes arise from the neuroepithelial cells of discrete neural 
tube regions (Ono et al., 1995). They first appear as so called oligodendrocyte precursor 
cells (OPCs) along the rostro-caudal extent at the ventral part of the spinal cord. In more 
rostral parts of the CNS the earliest oligodendroglial precursors are located in the 
ventricular and subventricular zone (Ono et al., 1997). Later, new sources of proliferation 
are available, such as the medial and lateral ganglionic eminence, from where new OPCs 
migrate into the developing cerebral cortex (reviewed in Miller, 2002).  
Proliferation, migration and maturation of oligodendrocytes are orchestrated by a variety 
of signaling molecules, but also by gene and protein expression. At the beginning both 
neuronal and oligodendroglial lineages respond to the signaling molecule sonic hedgehog 
and express the transcription factor Olig2 (Zhou et al, 2001). Later, combinatory 
expression of olig1, olig2 and Nk2 transcription factor related locus 2 (Nkx2.2) provides 
the generation of OPCs. At this stage OPCs can be detected with the monoclonal 
antibody A2B5, which is directed against a specific ganglioside epitope (Zhou et al., 
2001). Further, migrating early progenitors express the sulfated proteoglycan 
neuronal/glial 2 (NG2) and the platelet derived growth factor receptor α (PDGF-αR), by 
which they can be distinguished from neuronal precursors. Motoneurons also express 
Olig2, but they follow the neuronal lineage by additional expression of Ngn1 and Ngn2 
(Lu et al., 2002). Once departed from the neuronal lineage, precursors differentiate to 
astrocytes and oligodendrocytes and are therefore termed oligodendrocyte-type-2 
astrocyte (O-2A) progenitor cells (Raff et al., 1984). OPCs continue their maturation and 
express galactosulfatide, which is detectable using the monoclonal anti-oligodendrocyte 
marker O4 (Warrington and Pfeiffer, 1992). O4-positive OPCs, also termed late OPCs are 
postmigratory but still proliferative (Pfeiffer et al., 1993).  
After migration from the germinal zones, OPCs evenly distribute in gray and white 
matter followed by a wave of differentiation spreading from the corpus callosum towards 





Differentiation is mediated by down regulation of NG2 and PDGF-αR. In addition, 
myelin proteins are expressed such as MAG, CNP, MBP but not PLP and MOG. Finally, 
myelinating oligodendrocytes express PLP and MOG. Premyelinating oligodendrocytes 
which do not differentiate to myelinating oligodendrocytes undergo apoptosis, occurring 
in approximately 50% of these cells. However, a small population of proliferative late 
OPCs remains in the adult CNS after development.         
 
(Figure obtained from Miller, 2002) 
Figure 1: Proliferation and differentiation of oligodendrocytes during development 
Developmental oligodendroglial precursor cells (OPCs) derive from the subventricular zone (SVZ) of the neural tube. Upon the 
proliferative and migratory effects of hormonal factors such as platelet-derived growth factor (PDGF) and fibroblast growth factor 
(FGF), early OPCs can be detected using the monoclonal antibody A2B5. During the transition from proliferation to differentiation of 
oligodendroglial cells, the expression of surface antigens such as galactocebroside (GC) and galactosulfatide (which can be recognized 
by the monoclonal antibody O4) increases. Myelin proteins such as myelin basic protein (MBP) and proteolipid protein (PLP) are 







1.3.2 Proliferation and differentiation promoting factors 
A variety of trophic factors promote proliferation. As an example, plateled derived 
growth factor (PDGF) which is released by astrocytes and neurons, increases 
proliferation of OPCs by acting on its receptor PDGFαR (Noble et al., 1988; Pringle et 
al., 1992; Yeh et al., 1991). PDGF is not only a potential mitogen, it is also required for 
oligodendroglial survival (Fruttiger et al., 1999). The beneficial effects of PDGF are 
enhanced by the presence of the chemokine (C-X-C motif) ligand 1 (CXCL1) (Robinson 
et al., 1998). Moreover, CXCL1 regulates the migration of immature progenitors (Tsai et 
al., 2002). The basic fibroblast growth factor (FGFb) also supports proliferation by 
enhancing the expression of PDGF-αR on OPCs (McKinnon et al., 1991). Further 
promoters of proliferation are neurotrophin-3 (NT3), fibroblast growth factor 2 (FGF2), 
neuregulin-1 (NRG1) and its receptor  eukaryotic ribosome biogenesis protein 2 (Erb2) 
(Barres et al., 1994, Qian et al., 1997; Vartanian et al., 1999; Park et al., 2001).   
Differentiation is accompanied by upregulation of TGF-β. Additionally, the numbers of 
precursors can be controlled by altering the availability of survival factors such as PDGF. 
Proliferation and differentiation mechanisms mesh, as factors which promote 
differentiation on the one hand, in turn inhibit proliferation (Lazzarini, 2004). 
 
1.3.3 Adult oligodendrogenesis 
After development, a quiescent population of NG2 and PDGFαR expressing OPCs 
remains in the adult CNS. In contrast to developmental OPCs, adult OPCs show a more 
mature phenotype as they also express O4 (Dawson et al., 2000). Adult OPCs derive 
from developmental ones or from type B cells of the subventricular zone (Wren et al., 
1992; Lazzarini, 2004). Adult OPCs are abundant in the CNS and account for between 3 
to 9% of all cells. Further, spinal cord OPC:oligodendrocyte ratio is 1:4, whereas 1:1 ratio 
was found in gray matter (Dawson et al., 2003). The reason why adult OPCs do not 
differentiate to oligodendrocytes and why they remain as a quiescent abundant population 
is still unknown. Likely, gray matter environment arrests oligodendrocyte differentiation 
in an immature state, by the relative down regulation of humoral factors to a sub-





2004). However, adult OPCs are considered to differentiate to myelinating 
oligodendrocytes and replace lost ones, providing a potential source of remyelination in 
the diseased CNS, as occurring in MS and experimental demyelination. The higher ratio 
of OPC:oligodendrocyte in cerebral cortex compared to spinal cord provides a potent 
source of remyelinating cells that could explain the relatively effective cortical 
remyelination in MS patients (Lazzarini, 2004). Other studies indicate that OPCs may be 
involved in synaptic function (Bergles et al., 2000; Jabs et al., 2005; Karadottir et al., 
2008). 
As in developmental myelination, remyelination is associated with the upregulation of the 
transcription factors Olig2, Nkx2.2, myelin transcription factor 1 (Myt1) and Sry-related 
HMG box (Sox2) (Fancy et al., 2004; Watanabe et al., 2004; Talbott et al., 2005; Vana et 
al., 2007). Furthermore, adult OPC proliferation and differentiation is promoted by 
humoral factors. The most potent mitogen is PDGF acting via its receptor PDGFαR, 
which is uniquely expressed on OPCs (Noble et al., 1988; Wolswijk et al., 1991). FGF 
stimulates proliferation, partly by enhancing PDGFαR expression, and inhibits 
differentiation on the other hand (Besnard et al., 1989; Bansal and Pfeifer et al., 1994; 
McKinnon et al., 1990). The role of NT3 in adult oligodendrogenesis is not clear so far. 
However, studies indicate both, proliferative and differentiative effects of NT3, acting in 
combination with PDGF and basic fibroblast growth factor (bFGF) (Ibarrola et al., 1996; 
McTigue et al., 1998). Insulin-like growth factor-1 (IGF-1) increases proliferation and 
survival, enhances differentiation, and modulates expression of MBP in both OPCs and 
oligodendrocytes (Barres et al., 1992; McMorris and Dubois-Dalcq, 1988; Saneto et al., 
1988). 
 
1.4 Animal models of MS 
1.4.1 Toxin-induced demyelination models 
A number of animal models are available to study MS pathology and demyelination. One 
of the most used approaches is the injection of gliotoxic agents into locations of the CNS, 





takes place in almost all of these lesions, toxin induced demyelination provides a potent 
tool to study endogenous remyelination and oligodendrocyte recruitment, but also the 
engraftment of transplanted cells.  
Lysolecithin (lysophosphatidyl choline) is a membrane solubilizing agent and was first 
used in experimental demyelinaton by Hall (Hall, 1972). Injection into the rat dorsal 
funiculus produces ellipsoid shaped demyelination which extends longitudinally over 3 to 
8mm. Lysolecithin has a particular toxicity for myelin and oligodendrocytes. However, 
marginal loss of axons and astrocytes occurs in the point of injection. Following 
demyelination, oligodendrocyte and Schwann cell remyelination takes place. 
Injection of ethidium bromide into the rat spinal cord results in much larger areas of 
demyelination than in the lysolecithin model (Yajima and Suzuki, 1979; Blakemore et al., 
1982). This deoxyriribonucleic acid (DNA) intercalating agent kills oligodendrocytes, 
oligondendrocyte precursors and astrocytes. Both oligodendrocyte and Schwann cell 
remyelination takes place, depending on location and species (Woodruff and Franklin, 
1999; Jeffery and Blakemore, 1997). As mentioned above, spontaneous remyelination 
occurs in all toxin-induced demyelination models. Therefore, the contribution of 
engrafted cells is difficult to evaluate. For this reason, X-radiation prior to gliotoxin 
injection is used to deplete the local OPC population and inhibit endogenous 
remyelination (Hinks et al., 2001). Exogenous remyelination via cell transplantation can 
then be investigated in this model.  
The cuprizone mouse model is a widely used non-invasive model to investigate effects 
directly related to demyelination and remyelination within the CNS (Blakemore, 1973; 
Matsushima and Morell, 2001). Feeding young adult mice with the cuprizone (bis-
cyclohexanone-oxalhidrazone) for 5 weeks results in synchronous and consistent 
demyelination of the corpus callosum. Furthermore, strong spontaneous remyelination 
occurs rapidly after cuprizone removal from the diet. 
In addition to aforementioned models demyelination can be induced by the injection of 
anti-galactocerebroside antibodies and complement (Keirstead and Blakemore, 1997). 
Compared to gliotoxins, lesions involve a greater area of the dorsal funiculus, but in turn 






Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating 
disease of the CNS. EAE was first described by Rivers and colleagues in 1933 who 
observed that vaccination with rabbit CNS homogenate resulted in brain inflammation in 
rhesus monkeys (Rivers et al., 1933). Today EAE is the most used animal model of MS 
and acute disseminated encephalomyelitis (ADEM). EAE is nowadays induced by active 
immunization with a single injection of defined myelin peptides/proteins such as MBP, 
PLP and MOG (Kabat et al., 1951; Gold et al., 2006). The disease can be reliably 
induced in many different species, such as in the marmorset monkey, guinea pig, mouse 
and rat. Depending on the genetic background of the species or strain and the antigen 
used for vaccination, EAE reproduces many clinical and immunopathological aspects of 
MS (Hohlfeld and Wekerle, 2001; Gold et al., 2006).  
The autoimmune response against myelin sheath components is driven by 
encephalitogenic CD4-positive T cells (Ben-Nun et al., 1981). This is enabled by 
professional APCs which present antigen to fully reactive T cells (Dustin and Cooper, 
2000). In addition, B cell derived autoantibodies play an important role in rat and 
marmorset leading to extensive demyelination, but not in mice (Schluesener et al., 1987; 
Linington et al., 1988; Genain et al., 1995; von Budingen et al., 2004). Furthermore, 
components of the innate immune system like macrophages and Toll-like receptors are 
involved in disease pathogenesis (Takeda et al., 2003; Munz et al., 2005). 
Clinically, EAE disease is evaluated by a standardized EAE clinical score, the equivalent 
to the expanded disability status scale (EDSS) used in humans (Kurtzke, 1983). The 
clinical course of EAE can be either monophasic as in rats immunized with MBP, 
relapsing-remitting like in PLP/MOG peptide-immunized SJL mice, or secondary 
progressive such as observed in antibody high (ABH) Biozzi mice (Pender, 1987; Fritz et 
al., 1983; McRae et al., 1992; Hampton et al., 2008, Gold et al., 2006).  
To date, MOG is the only antigen that induces a significant demyelinating antibody-






1.4.3 Targeted cortical EAE model 
Studying cortical MS pathology is hampered by the lack of adequate animal models, as 
conventional EAE predominantly affects the spinal cord, but rarely the brain. Indeed, 
toxin-induced demyelination approaches are available, however, they do not reflect the 
autoimmune nature of MS. To overcome this limitation the targeted cortical EAE model 
was established by Merkler and colleagues (Merkler et al., 2006). Lewis rats are 
subcutaneously immunized with a subthreshold dose of MOG which leads to production 
of anti-MOG autoantibodies, but not to overt neurological symptoms. Following 
peripheral immune priming, lesions are induced by injection of pro-inflammatory 
cytokines into the cerebral cortex.  
The underlying concept of this model is that application of TNF-α/IFN-γ locally attracts 
blood born monocytes and lymphocytes into the target area, going inline with transient 
BBB leakage. This allows vaccination derived anti-MOG autoantibodies to penetrate into 
the CNS paremchyma and to bind to their epitopes on the myelin surface. Finally, 
demyelination is mediated by a combination of complement and antibody-dependent 
cellular cytotoxicity mechanisms (Linington et al., 1988; Gold et al., 2006). 
Histopathologically, the targeted cortical EAE model is characterized by extensive 
subpial and intracortical demyelination and oligodendroglial loss. The subpial lesions are 
reminiscent to cortical type III lesions observed in MS patients (Merkler et al., 2006; 
Peterson et al., 2001). In addition, demyelination is accompanied by 
microglia/macrophage activation, CD4- and CD8-positive T cell infiltration, and 
complement deposition. Furthermore, an acute axonal damage but no substantial neuronal 
loss was observed. In contrast to targeted white matter lesions, extensive cortical 
remyelination takes place and inflammation resolves within two weeks post lesion 
induction (Kerschensteiner et al., 2004; Merkler et al., 2006). For mentioned reasons, 










The failure to achieve remyelination is considered to play an important role in MS, 
however the mechanisms causing this failure are not fully understood. Inadequate 
provision of OPCs is a proposed cause of impaired or total lack of myelin restoration. A 
further hypothesis describes how OPCs, after being recruited into the sites of 
demyelination fail to differentiate to remyelinating oligodendrocytes. Irrespective of the 
aforementioned theories and age-dependent effects, frequency of demyelinating events 
may also play a role in MS. The reason for focussing on the cerebral cortex is based upon 
its ability to remyelinate during early stages of the disease, even after indications of 
repetitive demyelinating events. However, limited or impaired myelin restoration in 
patients with long disease duration indicates an exhaustion of the remyelination capacity.    
My thesis addressed whether chronic demyelinated lesions within the cerebral cortex in 
MS patients are the result of repetitive demyelinating episodes.  
The aims were: 
1. to  induce repetitive inflammatory demyelinated lesions within  the same cortical 
area in the targeted cortical rat EAE model of MS 
2. to characterize de- and re-myelination after repeated lesion inductions 
3. to characterize oligodendroglial recruitment in targeted cortical EAE lesions 
4. to investigate the effects of repeated targeted cortical EAE lesions on 
inflammation and axonal density 
Material and Methods  
2. MATERIALS AND METHODS 
 
The study was carried out at the laboratories of the Department of Neuropathology and 
the animal house (Zentrale Tierexperimentelle Einrichtung, ZTE) of the University 
Medical Center, Göttingen, according to the approval of the Bezirksregierung 
Braunschweig.  
 
2.1 Study design 
Our objective in the present study was to determine whether repetitive demyelinating 
cortical episodes may exhaust the intrinsic cortical remyelinating capacity. For this 
purpose, we induced repeated lesions (each of which simulates a “demyelinating 
episode”) at fixed intervals and a defined location in the rat cortex followed by 
histological assessment at different time points. 
In the classical rodent EAE model, lesions are mostly confined to the spinal cord but only 
rarely affected the cerebral cortex. Therefore, a new model of MS was established that 
allows for EAE lesions to be targeted in the cerebral cortex with high accuracy in terms 
of the time point and location of lesion evolvement as well as lesion recovery (Merkler et 
al., 2006). In this animal model, rats are immunized with a subclinical dose of 
recombinant myelin oligodendrocyte glycoprotein (rMOG). Subclinical MOG 
immunization induces anti-MOG antibodies without overt clinical symptoms per se. In a 
second step, pro-inflammatory mediators are stereotactically injected into the rat cerebral 
cortex 1 mm caudal to bregma and 2 mm lateral to the sagittal suture, which finally 
induce focal extensive subpial and intracortical lesions (Figure 2). According to Paxinos 
stereotactic brain atlas, the affected area includes the motor (M1) and sensory cortex (S1) 
and allows for future behavioural analysis with regard to putative motor and sensory 
implications (Paxinos, 1998). The time points chosen for histological evaluation include 
the maximum extent of demyelination, which occurs at day 3 post lesion induction and 
remyelination at day 21. Lesioning was then repeated at the same particular area a total of 
four times at 21-day intervals, thus providing the necessary time for recovery between 
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after the first, second and fourth lesioning episodes. Histological analysis was performed 
with respect to demyelination, remyelination, recruitment of oligodendrocytes, 
inflammatory infiltrates and axonal integrity. By computer-aided and manual analysis, 
the following parameters were analyzed and quantified: demyelinated area, fraction of 
myelinated fibres and cell densities.    
In order to investigate oligodendrocyte recruitment in more detail, the proliferative 
kinetics of oligodendroglial populations in response to demyelination was analysed. 
Therefore, animals were labelled with the proliferation marker 5-bromo-2-deoxyuridine 
(BrdU), which is incorporated in dividing cells.  
High and stable serum levels of anti-MOG autoantibodies are an important prerequisite 
for induction of demyelinating episodes. Therefore, serum levels of MOG autoantibodies 
were monitored by ELISA beginning from the initial lesion (day 18 post immunization) 
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2.2 Animals and groups 
A total number of n=101 adult female Lewis rats (195g ± 15, Harlan, Horst, Netherlands) 
were included in this study. The animals were kept in groups (max. 8 animals per cage) 
on a 12:12 h light/dark cycle with food and water provided ad libitum. All experiments 
were approved by the Bezirksregierung Braunschweig, Germany.  
This study consisted of 5 independent experiments from which 4 were pooled for the 
repetitive lesioning approach (Table 1), as interexperimental variations were negligible. 
In an additional experiment, proliferation of oligodendroglial cells were analysed in more 




days post injection* 
2nd injection 
days post injection* 
4th injection 
days post injection* 
3 21 3 21 3 21 
s.c. MOG 9 11 7 5 8 18 
s.c. IFA 6 - - - 4 - 
no 6† - - - - - 
* sacrifice of animals; † 3 of 6 animals were killed immediately after injection 




days post injection* 
3 21 21‡ 
s.c. MOG 4 6 - 
s.c. IFA 5 6 6+
* sacrifice of animals; ‡ intracerebral PBS injection instead of cytokines 
                                   + the contralateral side was used as a control and termed “non-injected”   
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2.3 Solutions and reagents 
 
Phosphate buffered saline (PBS): 
PBS (Dulbecco, Biochrom AG) 9.55g 
distilled water    1000ml 
 
1M sulfuric acid: 
 96% sulfuric acid (Merck)  51.1ml 
 distilled water    448.9ml 
 
4% paraformaldehyde (PFA): 
PFA (Merck, Germany)  40g 
1.0 M sodium hydroxide   1 drop 
10-fold PBS    100ml 
distilled water    9000ml  
adjust to pH 7.3 
 
0.05% Triton containing phosphate buffered saline (PBST): 
PBS      1000ml 
Triton X-100 (MP Biomedicals) 500µl 
 
Bielschowsky silver staining: 
20% silver nitrate solution: 
 silver nitrate (Roth)   10g 
 distilled water    50ml 
 
Developer stock solution: 
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 citric acid (Merck)   0.5g 
 65% nitric acid (Merck)  2 drops 
 distilled water    100ml 
 
2% sodium thiosulfate solution: 
sodium thiosulfate pentahydrate 10g 
(Merck) 
distilled water    500ml 
 
H & E staining: 
1% acid rinse: 
30% hydrochloric acid  2ml 
100% Isopropyl alcohol (Merck) 198ml 
 
1% eosin solution: 
 Eosin-G Certistain© (Merck)  2ml 
 70% isopropyl alcohol  198ml 




10mM citric acid buffer: 
citric acid (Merck))   2.1g 
distilled water    1000ml 
adjust to pH 6 
 
Tris-ethylenediaminetetraacetic acid (Tris-EDTA) buffered saline:  
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1.0M EDTA    1ml 
distilled water    1000ml 
adjust to pH 9 
 
0.2% casein block: 
 Tropix (Applied Biosystems)  2g 
 PBS     1000ml 
 Tween 20 (Merck)   1ml 
 heat Tropix/PBS to 50°C until it dissolves 
 
1.0M Tris/HCl stock solution: 
 trizma base (Sigma)   121g 
 30% hydrochloric acid  400ml 
 sodium chloride (Merck)  170g 
 distilled water    fill up to 1000ml 
 adjust to pH 7.5  
  
TBS working solution (washing buffer for immunohistochemistry): 
 sodium chloride (Merck)  9g 
 1.0M  Tris/HCl   50ml 
adjust to pH 7.5 
 
Fast Red working solution: 
 0.1M TBS (pH 8.2)   49ml 
naphtol-ASMX-phosphate (Sigma) 10mg 
 dimethylformamide (Sigma)  1ml 
 1.0M levimasole (Sigma)  50µl 
 Fast Red TR salt (Sigma)  0.05g 
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3,3’-diaminobenzidine tetrachloride (DAB) working solution: 
 DAB (Sigma)    25mg 
 PBS     50ml 
 30% hydrogen peroxidase (Merck) 30µl 
 
1% nickel ammonium sulfate solution: 
 nickel ammonium sulfate (Merck) 0.1g 
 distilled water    10ml 
 
4-nitro blue tetrazolium chloride (NBT) stock solution: 
70% N,N-dimethylformamide  1ml 
(Sigma) 
NBT (Roche)    100mg 
 
5-bromo-4-chloro-3-indolyl phosphate (BCIP) stock solution: 
70% N,N-dimethylformamide   1ml 
(Sigma) 
BCIP (Roche)    50mg 
 
NBT/BCIP buffer: 
1.0M Tris (Sigma-Aldrich)  100ml 
5.0M NaCl (Merck)   20ml 
1.0M MgCl (Merck)   50ml 
distilled water    100ml      
 
NBT/BCIP working solution: 
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BCIP stock solution   175µl 
NBT/BCIP buffer   50ml 
 
 
2.4 Operations and procedures 
2.4.1 Immunogen 
Recombinant MOG (rMOG) was produced as described by Adelmann and colleagues 
(Adelmann et al., 1995). Briefly, rMOG corresponding to the N-terminal sequence of rat 
MOG (amino acids 1-125) was expressed in Escherichia coli and purified to 
homogeneity. The purified protein was dissolved in 6 mol/l of urea and dialysed against 
20 mmol/l of sodium acetate buffer (pH 3.0). Finally, the sample was stored at -70°C.  
 
2.4.2 Sensitization procedure 
Rats (n = 68) were anaesthetized by inhalation anaesthesia with isoflurane (Abbot, 
Germany) and injected subcutaneously at the base of tail with a total volume of 100µl of 
rMOG (50µg MOG diluted in saline) emulsified in incomplete Freund‘s adjuvant (IFA; 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany). For control experiments, rats (n = 
27) were injected subcutaneously at the base of the tail with a total volume of 100µl of 
saline emulsified in IFA. A subset of animals (n=6) received no s.c. injection (native 
controls). For induction of a targeted EAE lesion, MOG-sensitized rats were kept for 19-
21 days and then given a stereotactic injection of cytokines into a predetermined location 
of the cerebral cortex. 
 
2.4.3 Intracerebral stereotactic injection 
Animals were anaesthesized by intraperitoneal (i.p.) injection of ketamine 60mg/kg 
bodyweight (Inresa, Freiburg, Germany) and xylazine 8mg/kg bodyweight (Riemser, 
Greifswald, Germany). One ml of warmed sterile saline was administered subcutaneously 




Material and Methods  
of consciousness, the rats were mounted on a stereotactic device (Stoelting Co, IL, USA). 
A fine hole was then drilled through the scull 1 mm caudal to bregma and 2 mm lateral to 
the sagittal suture. To minimize the risk of brain damage, the drilling head was removed 
before penetrating the scull. The remaining thin scull was then opened by a fine scalpel, 
giving access to the surface of the brain. A finely calibrated glass capillary (Braun, 
Germany) was then stereotactically inserted, targeting the cortex at approximately 1.7 
mm depth. The rats were then injected with 1µl of a cytokine mixture composed of 250 
ng of recombinant rat tumour necrosis factor-α (TNF-α; R&D Systems, Abingdon, UK) 
and 150 U of recombinant rat interferon-γ (IFN-γ; PeproTech, London, UK) dissolved in 
phosphate-buffered saline (PBS, Dulbecco instamed, Biochrom AG, Germany) over a 3-
min period. A trace of monastral blue (Fluka, Germany) was added as a marker dye for 
better visibility. Unsensitized (native) control animals (Table 1) and a subgroup of s.c. 
MOG immunized animals (Table 2) received PBS and monastral blue alone. After 
injection, the capillary was carefully withdrawn and the operation site was sealed by 
suture. To provide analgesia, Temgesic© (Essex Pharma GnbH, Germany) was 
administered at 0.03mg/kg during surgery and 6 hours later. Stereotactic cytokine 
injection was performed up to four times at intervals of 21 days, always targeting the 
same area (Tables 1 and 2).  
 
2.4.4 5-bromo-2-deoxyuridine (BrdU) injection 
To determine proliferation of oligodendroglial cells after lesion induction, BrdU labelling 
was performed. A subset of s.c. MOG (n=44) and s.c. IFA (n=17) immunized animals  
were injected intraperitonealy twice daily with 1.5ml 0.9% NaCl solution (Braun, 
Germany) containing 100mg/kg (animal weight) 5-bromo-2-deoxyuridine (BrdU, Sigma). 
In a subgroup of animals, BrdU administration was started immediately after a single 
lesion induction and continued until the animals were sacrificed at day three post lesion 
induction. In animals which were kept for 21 days after lesion induction, BrdU was 
administered for 5 days starting at day 2 after each final intracerebral cytokine/PBS 
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2.4.5 Blood sampling and serum preparation 
In a randomly selected group of animals, blood samples were taken 1-3 days before and 
18-21 days after each intracerebral cytokine injection. Therefore, the rats were shortly 
anaesthetized by gas inhalation with isoflurane (Abbot, Germany). Following loss of 
consciousness, a blood sample (approx. 1ml) was immediately taken from the sublingual 
vein. Bleeding was then stopped by pressing a piece of cotton soaked in iron (III) 
chloride on the tongue. Collected blood samples were centrifuged (Centrifuge 5415 R, 
Eppendorf, Germany) at 13000rpm for 10min. The supernatant was then taken off and 
stored at -20°C for further measurements. 
 
2.5 Enzyme-linked immunosorbent assay (ELISA) for detection of anti-MOG 
autoantibodies 
To monitor the immune response, anti-MOG autoantibody serum levels were determined 
by ELISA. As a first step, 96-well maxisorp microtiter plates (Nunc, Langenselbold, 
Germany) were coated with rMOG at 0.4µg/50µl/well dissolved in PBST (phosphate 
buffered saline + 0.05% Triton). The plates were then wrapped in damp towels and stored 
at room temperature for 4 hours. Afterwards, the content was discarded by inverting the 
plates and tapping the bottom on paper towels. Plates were then blocked with 5% bovine 
serum albumin (BSA, Serva) dissolved in PBS (200µl/well) for 1h at room temperature 
and washed subsequently 5 times with water. As a last step, wells were filled with 200µl 
each and incubated for 15min at room temperature. Before storing at -20°C the plates 
were tapped on paper towels as described earlier.  
Rat sera were prepared by diluting 1:100 in PBST. In addition, 1:3 serial dilutions of each 
sample were added on a MOG coated plate starting with the upper row. The plates were 
then kept humid for 2h at room temperature. To remove unbound antibodies, plates were 
washed 6 times with PBST. Afterwards, 50µl of IgG-specific horseradish peroxidise-
conjugated goat anti-rat antibody (1:10000 in PBST; Pierce, Rockford, IL, USA) was 
added to each well and kept humid for 2 hours at room temperature. Following proper 
washing with PBST (6 times) 50µl of 3,3’-5,5’-tetramethylbenzidine (BM-Blue, POD; 
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developed a blue colour, reaction was stopped immediately by adding 50µl of 1M H2SO4 
(Merck) to all wells. Finally, optical density (OD) was measured at 450nm (Model 680, 
Bio-Rad, Hercules, CA, USA). Antibody titres were defined as the serum dilutions at half 
maximum OD.  
 
2.6 Histology 
2.6.1 Tissue processing 
2.6.1.1 Perfusion and sectioning 
Animals were anaesthetized by injecting a lethal dose of 14% chloral hydrate (Merck). 
After loss of consciousness, transcardial perfusion was performed through the left cardial 
ventricle with PBS followed by 4% paraformaldehyde. Brains were then dissected and 
stored for 24h in 4% paraformaldehyde at 4°C. After fixation, the brain was cut in 4mm 
thick slices and washed in water. In addition, slices were gradually dehydrated by 
performing alcohol/xylol/paraffin series overnight using an automated tissue processor 
(Thermo Scientific, Germany). The next day, slices were embedded in paraffin. Tissue 
blocks were then cut in 1-2µm thin coronal sections. Serial sections adjacent to the 
injection site were used for further histology (injection site was recognized/identified by 
traces of monastral blue).  
 
2.6.1.2 Deparaffination and dehydration of histological sections 
Prior to histological stainings, sections were deparaffinized by performing graded xylol 
(Merck) and isopropyl alcohol (Merck) series as follows: 4 x 100% xylol (8min), 1 x 
xylol/alcohol (1:1, 1min), 2 x 100% alcohol (4min), 1 x 90% alcohol (4min), 1x 70% 
alcohol (4min), 1x 50% alcohol (4min), 1x distilled water. 
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2.6.2 Histochemical stainings 
2.6.2.1 Hematoxylin and eosin (HE) staining 
HE staining was performed to obtain a general overview with regard to inflammation and 
astrocytosis. Sections were deparaffinized as described above, washed 3 times with 
distilled water and placed into Mayers Hämalaun (Merck, Germany) for 5 min. 
Afterwards, sections were washed with distilled water and differentiated by dipping 
slides once into 1% acid rinse. Subsequently, bluing was performed by bathing slides in 
flowing tap water for 10min. Slides were then washed in distilled water and placed into 
eosin solution for 5min. In addition, slides were washed (once again) in distilled water 
and dehydrated as described earlier. Alcohol series were performed quickly to avoid 
excessive elution of eosin. Finally, slides were mounted using DePex mounting medium 
(VWR International, Germany) and coverslipped.   
 
2.6.2.2 Bielschowsky silver staining (modified) 
To assess axonal integrity Bielschowsky silver staining was performed. Sections were 
deparaffinized as described earlier and washed 3 times with distilled water. Afterwards, 
sections were placed in 10% silver nitrate solution for 20min. Concentrated (32%) 
ammonium hydroxide (Merck, Germany) was added drop by drop to the nitrate solution 
until the formed precipitate cleared.  Following washing in distilled water, the slides were 
placed into the silver nitrate/ammonium hydroxide solution for 15min and kept dark.  
While washing the slides in distilled water (containing few drops of ammonium 
hydroxide), 10 drops of developer stock solution was added to silver nitrate/ammonium 
hydroxide solution using a stirrer. Subsequently, the slides were placed into this solution 
for about 1 minute until color of the tissue turned to ochery. In addition, excessive silver 
nitrate was washed out using 2% sodium thiosulfate solution. After a final wash with 
distilled water, slides were dehydrated as described earlier and mounted using DePex 
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2.6.3 Immunohistochemistry 
2.6.3.1 Antigen retrieval 
Loss of immunoreactivity caused by paraformaldehyde fixation can be reversed if tissue 
is exposed to heat and acid: 
Hydrated and washed slides were placed in closed polystyrene cuvettes filled to the top 
with 10mM citric acid (pH=6) or 1mM Tris-EDTA (pH=9) buffered saline. Slides were 
heated 5 times for 3 min using a microwave oven (800watt, Bosch). Between each 
incubation cycle (step), cuvettes were filled up alternately with buffer and distilled water. 
Before continuing further staining procedure, slides were left to cool down for 30min and 
then washed with distilled water.  
 
2.6.3.2 GFAP immunohistochemistry 
Reactive astrogliosis was assessed by immunohistochemistry using glial fibrillary acidic 
protein (GFAP) as a marker for astrocytes. Slides were washed 5 times in PBS between 
each step. Following deparaffination, endogenous peroxidases were blocked by placing 
slides in 3% hydrogen peroxide (dissolved in PBS) for 20min at 4°C. Unspecific antibody 
binding was performed by applying 100µl 10% fetal calf serum (FCS, Biochrom) for 30 
min. Afterwards, excessive FCS was removed with a cleaning wipe without washing with 
PBS. The primary antibody mouse anti-human GFAP (1:50, clone 6F2, Dako) was added 
overnight at 4°C. Biotinylated sheep anti-mouse (1:200, Amersham) and ExtrAvidin 
(1:1000, Sigma) were applied consecutively for 1h at room temperature. Color 
development with DAB was performed for approximately 5min followed by 
counterstaining with Mayers Hämalaun (Merck, Germany). Finally, slides were 
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2.6.3.3 MBP immunohistochemistry 
Demyelination and remyelination was assessed by immunohistochemistry using MBP as 
a marker for myelin sheaths. Slides were washed 5 times in PBS between each step, 
blocking of unspecific antibody binding being an exception. Following deparaffination, 
endogenous peroxidases were blocked by placing slides in 3% hydrogen peroxide 
(dissolved in PBS) for 20min at 4°C. Unspecific antibody binding was performed by 
incubation with 100µl 10% fetal calf serum (FCS, Biochrom) for 30 min. The primary 
antibody, rabbit anti-human MBP (1:1500, A0623, Dako), was added overnight at 4°C. 
Biotinylated donkey anti-Rabbit (1:200, Amersham) and ExtrAvidin (1:1000, Sigma) 
were applied consecutively for 1h at room temperature. Color development with DAB 
was performed for approximately 5min followed by counterstaining with Mayers 
Hämalaun (Merck, Germany).  In a subset of animals, color reaction was enhanced by 
adding 2.5ml of 1% nickel ammonium sulfate to the substrate solution (adjusted to pH 
7.2). Finally, slides were dehydrated and mounted using DePex mounting medium (VWR 
International, Germany) and coverslipped. 
 
2.6.3.4 ED1 immunohistochemistry 
Inflammation was assessed by immunohistochemistry using ED1 as a marker for 
macrophages and activated microglia, respectively. Slides were washed 5 times in PBS 
between each step. Following deparaffination, antigen retrieval (10mM citric acid and 
microwave irradiation) was performed as described above. Afterwards, endogenous 
peroxidases were blocked by placing slides in 3% hydrogen peroxide (dissolved in PBS) 
for 20min at 4°C.  Blocking of unspecific antibody binding was achieved by incubation 
with 100µl 10% FCS for 30min. Afterwards, excessive FCS was removed with a cleaning 
wipe without washing with PBS. The primary antibody, rabbit anti-human ED1 (clone 
ED1; Serotec, Oxford, UK), was applied overnight at 4°C. Biotinylated donkey anti-
rabbit (1:200, Amersham) and ExtrAvidin (1:1000, Sigma) were added consecutively for 
1h at room temperature. Color development with DAB was performed for approximately 




Material and Methods  
dehydrated and mounted using DePex mounting medium (VWR International, Germany) 
and coverslipped. 
 
2.6.3.5 MBP/NogoA double immunohistochemistry 
To determine the oligodendrocyte density within the lesion, double 
immunohistochemistry was performed using MBP as a marker for myelin sheaths and 
NogoA (clone 11C7) as a marker for mature oligodendrocytes. Antigen retrieval (10mM 
citric acid and microwave irradiation) was performed followed by blocking of 
endogenous peroxidases and unspecific antibody binding as described above (see 
2.5.3.4). The primary antibody, mouse anti-mAb11C7 (1:20000, kindly provided by M. 
E. Schwab, ETH Zurich), was added overnight at 4°C. Biotinylated sheep anti-mouse 
(1:200, Amersham) and ExtrAvidin (1:1000, Sigma) were applied consecutively for 1h at 
room temperature. Color development with DAB was performed for approximately 5min. 
To saturate open binding sites on the first primary antibody, 100µl of Fab antibody 
(mouse, Dako) was added followed by blocking of unspecific antibody binding sites 
using 100µl 10%FCS (containing 0.05% Triton-X-100, MP Biomedicals). The second 
primary antibody, rabbit anti-human MBP (1:1500, A0623, Dako), was applied for 2h at 
room temperature. Henceforth, 0.5M Tris buffered saline (TBS) was used for washing 
and incubation steps. Mouse anti-rabbit antibody bridge (1:50, Dako), goat anti-mouse-
alkaline phosphatase (AP) (1:50, Dako) and alkaline phosphatase anti-alkaline 
phosphatase (APAAP) mouse (1:50, Dako) were added consecutively for 1 hour at room 
temperature. Color reaction was performed using NBT/BCIP (Roche) as substrate. For 
representative photographs, some sections were stained using Fast Red as a substrate. 
Finally, slides were mounted with Immu-Mount (ThermoScientific) and coverslipped. 
 
2.6.3.6 Olig2/PLP double immunofluorescence 
To determine the oligodendroglial precursor density within the lesion, double 
immunofluorescence staining was performed using PLP as marker for myelin sheaths and 
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retrieval (1mM Tris-EDTA, pH=9, microwave heating) was followed by blocking with 
0.2% casein (Tropix, I-Block, Applied Biosystems) in PBS for 30min. The first primary 
antibody, rabbit anti-human olig2 (1:300 in 0.2% casein, IBL, Germany), was added 
overnight at 4°C. The indocarbocyanine 3 (Cy3) conjugated donkey anti-rabbit IgG 
(H+L) secondary antibody (1:300 in 0.2% casein, Dianova GmbH, Hamburg, Germany) 
was applied for 1h at room temperature. The second primary antibody, mouse anti-PLP 
(1:2500 in 10% FCS, clone Plpc1, Biozol), was added overnight at 4°C followed by 
indocarbocyanine 2 (Cy2) conjugated donkey anti-mouse IgG (H+L) secondary antibody 
(1:200 in 10% FCS, Dianova GmbH, Hamburg, Germany) for 1h at room temperature. 
Cell nuclei were stained with DAPI (1:10000 in 10%FCS, Molecular Probes) for 10min 
at room temperature. Finally, slides were mounted using Fluoromount (Dako) and 
coverslipped. 
 
2.6.3.7 NogoA/BrdU double immunohistochemistry 
To determine the mature oligodendrocyte population derived by cell division after lesion 
induction, double immunohistochemistry was performed. NogoA was used as a marker 
for mature oligodendrocytes. BrdU was used as a marker for previous cell division. 
Antigen retrieval (10mM citric acid and microwave irradiation) was performed followed 
by blocking of endogenous peroxidases and unspecific antibody binding as described 
above (2.5.3.4). The primary antibody, rabbit anti-NogoA (1:100 in 10% FCS, clone 
H300, Santa Cruz), was added overnight at 4°C. Henceforth, 0.5M Tris buffered saline 
(TBS) was used for washing and incubation steps till finishing the first staining. Goat 
anti-rabbit alkaline peroxidase (AP) conjugated antibody (1:50, D0487, Dako) was added 
for 45min at room temperature. Color reaction was performed using Fast Red (Sigma) as 
a substrate. The second primary antibody, mouse anti-BrdU (1:400 in 10% FCS, 
Chemicon), was applied overnight at 4°C.  Biotinylated sheep anti-mouse (1:200 in 10% 
FCS, GE Healthcare) and ExtrAvidin (1:1000, Sigma) were added consecutively for 1h at 
room temperature. Color development with DAB was performed for approximately 5min 
followed by counterstaining with Mayers Hämalaun (Merck). Finally, slides were 
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2.6.3.8 Olig2/BrdU double immunohistochemistry 
To determine the oligodendroglial precursor density derived by cell division after lesion 
induction, double immunofluorescence staining was performed using olig2 as a marker 
for oligodendroglial precursors/early oligodendrocytes and BrdU as a marker for 
proliferation. Antigen retrieval (Tris-EDTA and microwave heating) was performed 
followed by blocking with 0.2% casein in PBS for 30min. The first primary antibody, 
rabbit anti-human  olig2 (1:300 in 0.2% casein, IBL, Germany), was added overnight at 
4°C. The Cy3-conjugated donkey anti-rabbit IgG (H+L) secondary antibody (1:300 in 
0.2% casein, Dianova GmbH, Hamburg, Germany) was applied for 1h at room 
temperature. As a second primary antibody, mouse anti-BrdU (1:400 in 10% FCS, 
Chemicon) was added overnight at 4°C followed by Cy2-conjugated donkey anti-mouse 
IgG (H+L) secondary antibody (1:200 in 10% FCS, Dianova GmbH, Hamburg, 
Germany) for 1h at room temperature. Cell nuclei were stained with DAPI (1:10000 in 
10%FCS, Molecular Probes) for 10min at room temperature. Finally, slides were 
mounted using Fluoromount (Dako) and coverslipped. 
 
2.7 Photoimaging and morphometric analysis 
Histological photographs were captured through light and fluorescent microscopes (BX 
40 and BX 50, Olympus, Germany) at 20-, 40-, 200-, 400- and 1000-fold magnification, 
respectively. Images for computer-aided analysis were recorded with digital cameras 
mounted on mentioned microscopes (Color View II and DP71, Olympus, Germany).  
Histological stainings were analysed as followed: 
Digital images of MBP-stained sections were recorded through a light microscope (BX 
40, Olympus, Germany) with a CCD camera (Color View II, Olympus, Germany) at 200-
fold magnification. The size of demyelinated lesion was measured using Analysis 
software (Analysis, Soft Imaging System, Germany). The extent of demyelination was 
defined as the MBP-negative area (mm²). The length of subpial lesion was given in µm. 
The fraction of myelinated axons was determined in cortical layer III within 4 fields of 
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The numbers of MBP-positive myelin sheaths which overlapped the crosses of the 
counting grid were determined on MBP-stained sections. In addition, the numbers of 
axons were analysed in the same way on adjacent Bielschowsky-stained sections. 
Afterwards, MBP-positive fibre counts were normalized to axon counts, second been set 
to 100% as a reference.  
The macrophage/microglia reaction was determined on ED1-stained sections within two 
defined cortical areas. First, ED1-positive cells were counted in cortical layer III within 
the center of lesion within four fields of sight at 1000-fold magnification (Figure 3, A). 
To capture a broad area of inflammation, a further region of interest (ROI) was chosen. 
This ROI was defined as the cortical area lying within the upper quadrant of a 
standardized fictive rectangular cross, which was placed in the middle of the analyzed 
section orientated in the medial-lateral and dorsal-ventral direction, respectively (Figure 
3, C). For both ROIs, the mean number of ED1-positive cells per square millimetre was 
given.   
Axonal integrity was assessed on Bielschowsky silver-stained sections at 1000-fold 
magnification. Axons were determined in the center of lesion of cortical layer III within 4 
fields of sight using a 10x10 counting grid (Figure 3, A). Axonal density was given in 
percent using untreated control animals as a reference (set to 100%). 
NogoA-positive cell population was determined on NogoA/MBP double positive-stained 
sections at 400x-fold magnification. Proliferated NogoA-positive cells were determined 
on NogoA/BrdU double stained sections. The density of both cell populations were 
assessed in cortical layers I and II within 11 fields of sight of a 10x10 counting grid, 
covering the typically affected areas of subpial demyeliantion (Figure 3, B). Cell density 
was given as cells per square millimetre.  
Olig2-positive and olig2/BrdU-double positive cell populations were determined on 
olig2/BrdU double fluorescent stained sections using a light/fluorescent microscope (BX 
51, Olympus, Germany) at 200-fold magnification. Cells were counted in cortical layers I 
and II within three fields, which is similar to ROI used for evaluation of above mentioned 
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A cell was considered “positive” or “double-positive” when the following two conditions 
were met: 
First, the specific signal must overlap with the cell soma (NogoA, olig2, BrdU, ED1) or 
its dendritic processes (ED1). Second, a cell must contain a nucleus.   
 
 










Statistical analysis was performed using a statistical software package (SPSS Version 12 
for Windows, SPSS Inc., Chicago, IL, USA). Graphs were visualized with GraphPad 
version 5 for windows (GraphPad Software, San Diego, CA, USA). Normality of 
distribution was verified by Kolmogorow-Smirnov-test. Statistical calculations included 
one-way analysis of variance (ANOVA) if three or more groups were compared, 
followed by post-hoc least significance difference (LSD)-test. For comparisons between 
two groups, unpaired t-tests were performed. A probability value of less then 0.05 was 




3.1 Detection of anti-MOG autoantibody titres 
High and stable serum levels of anti-MOG autoantibodies are an important prerequisite 
for induction of targeted EAE lesions. Therefore, serum levels of MOG autoantibodies 
were monitored by ELISA at regular intervals. High and consistent anti-MOG 
autoantibody titres were detected in s.c. MOG immunized animals at all time points 
analysed (Figure 4). As expected, s.c. IFA immunized control animals did not reveal a 
significant antibody response against MOG.  
 
Figure 4: Anti-MOG autoantibody titres 
Titres of anti-MOG autoantibodies. Time-course analysis revealed high and consistent anti-MOG antibody titres in s.c. MOG 
immunized animals. S.c. IFA control animals did not reveal a detectable antibody response against MOG. Data are expressed as mean 
+ SEM. For statistical evaluation, one-way ANOVA was peformed.  
* antibody titres refer to the serum dilution needed to achieve half maximum OD  
 
3.2 Gliosis 
To analyse possible traumatic effects caused by surgical intervention, HE-staining and 
GFAP immunohistochemistry were performed. HE-staining revealed moderate gliosis 
and edema restricted to the close proximity of the injection site (Figure 5, A, D and E). 





immunoreactivity at similar areas to the HE-staining (Figure 6, A, C, F). In addition, 21 
days post lesion induction, a few s.c. MOG immunized animals presented with increased 
subpial GFAP-immunoreactivity in remyelinated cortical areas. Aside from these 
aforementioned cases, adjacent areas showed no pathological abnormalities (Figure 5, B 










Figure 5: HE-staining of local gliosis  
Representative photographs of HE-stained section of a cortical lesion (A-E). Moderate gliosis was observed at close proximity of the 
needle track (A/D/E). Edema and glial scar formation (D and E, indicated by arrows) were restricted to the immediate vicinity of the 
injection.  No pathological abnormalities were observed in adjacent areas within cortical lesion (B/C). 
















Figure 6: GFAP immunohistochemistry of local gliosis  
Representative photographs of GFAP-immunostained section of a cortical lesion (A-F). GFAP immunoreactivity was observed in 
close proximity to the injection site (A/C/F).  No pathological abnormalities were observed in adjacent areas within the cortical lesion 
(B//D/E). 
Scale bars: A = 250µm, B-F = 50µm 
 
3.3 Topology of de- and remyelination in the focal cortical EAE model 
MBP immunohistochemistry was performed to assess demyelination and remyelination, 





demyelination was observed in MOG primed animals (Figure 7, A-C). With regard to 
topology, a pronounced widespread subpial lesions was located at the site of injection 
(Figure 7, A-C), which often extended into deep cortical layers (layers 4-6). In the 
medial-lateral direction, demyelination extended more superficially (layers 1-3). The 
topography of these lesions was highly reminiscent of cortical type III lesions found in 
multiple sclerosis (Peterson et al., 2001). In addition, spots of perivascular lesions were 
distributed along the ipsilateral cerebral cortex (Figure 7, A and B). Similar lesion pattern 
and similar extent of demyelination was observed in animals which received two or four 
intracerebral cytokine injections (Figure 8). The contralateral non-injected hemisphere 
showed no signs of demyelination (Figure 7, D, E and F). Cytokine injection did not 
show substantial tissue damage in s.c. IFA immunized control animals, even after 
repetitive injections (Figure 8). Cortical demyelination is a transient phenomenon; 21 
days after lesion induction, extensive remyelination took place (Figure 8) and only few 
and small areas within the center of the lesion remained demyelinated. Even animals 
suffering from 2 or 4 demyelinating events showed extensive remyelination and did not 
















































Figure 7: Focal cortical EAE lesion  
Representative photographs of MBP immunostained cerebral cortex of s.c. MOG primed Lewis rats at day 3 post lesion induction (A-
F). Proinflammatory cytokines such as TNF-α and IFN-γ were targeted to the cerebral cortex (indicated by arrow with a blue traced 
needle track underneath), leading to extensive focal demyelination (lesion border indicated by dotted line) within the ipsilateral 
hemisphere (A-C). The contralateral non-injected hemisphere was not affected (D-F). 























Figure 8: Cortical demyelination and remyelination after repetitive lesion induction 
Representative photographs of MBP stained sections of cortical layer 3 (center of lesion). The different time points (days 3 and 21) 
and immunization protocols (s.c. MOG versus s.c. IFA) are arranged in columns. The numbers of lesion inductions (1st, 2nd and 4th) are 
arranged in rows. Repeated cortical demyelination (MBP-negative) was observed in s.c. MOG immunized animals 3 days after 
cytokine injection (left column). At 21 days after lesion induction, extensive remyelination (MBP-positive: dark stained fibres) took 
place, even after repetitive demyelinating events (middle column). S.c. MOG immunized control animals showed no signs of 
demyelination (right column).   
Scale bars: 100µm 
 
3.3.1 Extent of demyelinated area 
The extent of demyelination was quantified using computerbased analysis performed on 
photographs of MBP-stained sections. Intracerebral cytokine injection led to focal 
cortical demyelination in all s.c. MOG primed animals (Figure 9, A). Demyelinated area 
did not differ significantly between animals with singular induced lesions (1.53 x 106 ± 





(1.76 x 106 ± 3.12 x 105µm²) demyelinating episodes. Demyelinated area decreased 
significantly (one-way ANOVA F5,52 = 11,013, p < 0,001) twenty-one days after each 
previous demyelinating episode (post-hoc LSD-test: 1st inj. p < 0,001, 2nd inj. p = 0,002, 
4th inj. p < 0,001). No significant difference was observed comparing groups at day 21 
post lesion induction after single or repetitive lesioning. S.c. IFA immunized and 
cytokine injected control animals did not show any sign of demyelination.  
 
Figure 9: Extent of demyelination  
 (A) Extent of demyelination was determined on MBP-stained sections. Intracerebral cytokine injection following immunization with 
MOG led to extensive demyelination following each cytokine injection. Demyelinated area decreased significantly even after 





revealed similar outcome.  Data are expressed as mean + SEM. For statistical evaluation, one-way ANOVA followed by post-hoc 
LSD-test was performed (** = p< 0.01, *** = p< 0.001). 
 
3.3.2 Length of subpial lesions 
As an additional parameter, length of subpial lesion was measured. At day three post 
lesion induction, average subpial lesion length did not differ between singly induced 
lesions (5490 ± 670.3µm) compared to those animals with two (5769 ± 606.9µm) and four 
(5666 ± 621µm) demyelinating episodes (Figure 9, B). Twenty-one days after each 
previous lesion induction, length of subpial lesion decreased significantly (ANOVA F5,52  
= 14,936, p < 0,001) compared to those lesions measured at day 3 (post-hoc LSD-test: 1st 
inj. p < 0,001, 2nd inj. p = 0,001, 4th inj. p < 0,001). No significant difference was 
observed comparing groups at day 21 post lesion induction. As expected, s.c. IFA 
immunized control groups showed no signs of demyelination.  
3.3.3 Fraction of myelinated axons 
To determine the ratio of myelin density to axons, the fraction of myelinated axons was 
measured in de- and remyelinated areas of cortical layer III. Fraction of myelinated axons 
is defined as the ratio of MBP-positive fibres to axons (determined on Bielschowsky 
silver-stained sections). In untreated age matched control animals, a considerably high 
fraction of myelinated axons (mean 40.58 ± 2.67%) was determined. At day 3 post lesion 
induction, almost no myelin was detected in s.c. MOG immunized animals (Figure 10, 1st 
inj.: 1.27 ± 0.58%, 2nd inj.: 2.67 ± 1.12%, 4th inj.: 0.52 ± 0.34%). Twenty-one days after 
lesion induction, the fraction of myelinated axons (1st inj.: 16.22 ± 3.02%, 2nd inj.: 21.95 
± 3.84, 4th inj.: 16.64 ± 2.99%) increased significantly (one-way ANOVA F8,61=10,727 p 
< 0,001) in all s.c. MOG immunized groups (post-hoc LSD-test: 1st inj.: p = 0.012, 2nd 
inj.: p = 0.02, 4th inj.: p = 0.011). Comparisons between s.c. MOG immunized groups at 
day 21 revealed no significant statistical differences. Albeit a substantial fraction of axon 
remyelinated at day 21, the obtained values were still significantly lower as compared to 
the control groups (post-hoc LSD-test: 1st inj.: p < 0.001, 2nd inj.: p = 0.013, 4th inj.: p < 
0.001). At day 3 post lesion induction, fraction of myelinated axons was significantly 







Figure 10: Fraction of myelinated axons  
Fraction of myelinated axons was expressed as the percentage of myelin density normalized to axonal density. After each lesion 
induction, almost complete loss of myelin content was determined within the center of lesion of s.c. MOG immunized animals. 
Twenty-one  days after lesion induction, the fraction of myelinated axons recovered significantly. However, remyelinated lesions 
showed significantly reduced fraction of myelinated axons compared to normally myelinated cerebral cortex (untreated controls). In 
contrast, IFA immunized controls showed similar fraction of myelin as untreated controls. Data are expressed as mean + SEM. For 
statistical evaluation, one-way ANOVA followed by post-hoc LSD-test was performed (* = p < 0.05, ** = p < 0.01, *** = p < 0.001). 
 
3.4 Evaluation of activated macrophages/microglia 
To assess inflammatory activity during de- and remyelination, immunohistochemistry 
was performed using ED1 as a marker for activated macrophages/microglia. 
Demyelination was accompanied by inflammation (Figure 11). At day 3 after lesion 
induction, ED1-positive cells were detected within and near demyelinated areas (Figure 
11, H). With regard to morphology, two different ED1-positive cell types were observed: 
1) Ramified macrophages/microglia were the predominant population in s.c. IFA 
immunized control animals (Figure 11, G) but were also abundant within lesions 
of s.c. MOG primed animals. 
2) Foamy macrophages were mainly found at day 3 post lesion induction in s.c. 





Extensive and dense parenchymal infiltrates were predominantly located in the center of 
subpial lesions (Figure 11, E and H). In contrast, perivascular infiltrates (Figure 11, D) 
were also observed in nearby non-demyelinated cortical areas (Figure 11, H). 
Inflammation was more pronounced after single lesioning in both density and extent of 
activated macrophages/microglia. ED1-positive cells were also detected in repetitively 
injected animals, but macrophage/microglia activation seemed to be less pronounced 
compared to singly injected ones (Figure 12). Inflammation resolved 21 days after lesion 
induction. Just few ED1-positive cells were observed in close vicinity to the needle track, 
similar to s.c. IFA immunized control animals. The contralateral non injected side 
appeared normal and rarely few ED1-positive cells were detected in the subpial region of 









































Figure 11: Inflammatory demyelination in the focal cortical EAE model 
Representative photographs of the cerebral cortex of s.c. MOG primed Lewis rats at day 3 post lesion induction. Subpially 
demyelinated lesions (A and C, lesion border is indicated by dotted line) and perivascular lesions (A and B, lesions are surrounded by 
dotted circles) were identified by MBP immunohistochemistry (lesions are MBP-negative). Demyelination was accompanied by 
activation of microglia/macrophages visualized by ED1 immunohistochemistry (D-H). Perivascular (D) and parenchymal (E) spots of 
ED1-positive cells were distributed within and near demyelinated areas (H, see also A-C). Foamy macrophages indicating 
demyelination, were predominantly found at day 3 after lesion induction (F, indicated by arrow). Ramified ED1-positive cells (G, 
indicated by arrow) were observed in s.c. MOG primed demyelinated/remyelinated animals and s.c. IFA controls, respectively.  

























Figure 12: Transient activation of macrophages/microglia 
Representative photographs of ED1 stained sections of the lesioned cerebral cortex. The time points of histological evaluation (days 3 
and 21) and immunization protocols (s.c. MOG versus s.c. IFA) are arranged in columns. The numbers of lesion inductions (1st, 2nd 
and 4th) are arranged in rows. Strong activation of microglia/macrophages was observed in s.c. MOG immunized animals at day 3 post 
lesion induction (left column). Inflammation resolved within 21 days post lesion induction (middle column). In s.c. IFA immunized 
control animals, no substantial activation of microglia/macrophages was observed (right column). 
Scale bar: 100µm 
3.4.1 Density of activated macrophages within center of lesion 
Density of activated macrophages/microglia was analysed on ED1 stained sections in 
cortical layer 3 within the center of lesion:  
At day 3 post lesion induction, high densities of ED1-positive cells were detected after 





± 56.64cells/mm², 2nd inj.: 485.3 ± 52.81cells/mm², 4th inj.: 360.0 ± 66.32cells/mm²). 
After four demyelinating episodes, values decreased significantly (one-way ANOVA F7,59 
= 41,874, p < 0,001) compared to animals with a single (post-hoc LSD-test: p = 0.01) or 
two demyelinating episodes (post-hoc LSD-test: p = 0.022). Twenty-one days after each 
demyelinating episode, density of ED1-positive cells (1st inj.: 67.64 ± 13.05cells/mm², 2nd 
inj.: 70.4 ± 17.23cells/mm², 4th inj.: 57.33 ± 5.83cells/mm²) decreased significantly 
compared to day 3 animals (post-hoc LSD-test: 1st, 2nd and 4th inj.: p < 0.001) and were 
similar to s.c. IFA immunized control groups (1st inj.: 56.00 ± 10.73cells/mm², 4th inj.: 
72.00 ± 4.62cells/mm²). S.c. MOG immunized animals analysed at day 3 post lesion 
induction showed significantly increased values when compared to their corresponding 
s.c. IFA immunized control group (post-hoc LSD-test: 1st and 4th inj.: p < 0.001). 
3.4.2 Density of activated macrophages/microglia throughout all cortical layers 
As mentioned above, activated macrophages/microglia were also distributed beyond the 
border of demyelinated lesions. Therefore, quantification of activated 
macrophages/microglia was performed in a broad area including all cortical layers 
(Figure 3, B). Density of ED1-positive cells reached highest values at day 3 of singly 
injected s.c. MOG immunized animals (58.48 ± 10.75cells/mm², Figure 13, B). Although 
a substantial accumulation of ED1-positive cells were observed after two and four 
demyelinating episodes (2nd inj.: 28.80 ± 4.84cells/mm², 4th inj.:25.11 ± 3.99cells/mm²), 
their numbers were decreased (one-way ANOVA F7,59 = 19,031, p < 0,001) when 
compared to single injected animals (post-hoc LSD-test: 2nd and 4th inj.: p < 0.001). 
Twenty-one days after each demyelinating episode, density of ED1-positive cell counts 
(1st inj.: 4.77 ± 1.88cells/mm², 2nd inj.: 6.04 ± 1.29cells/mm², 4th inj.: 4.33 ± 
0.67cells/mm²) dropped sharply and significantly compared to day 3 animals (post-hoc 
LSD-test: 1st inj.: p < 0.001, 2nd inj.: p = 0.007, 4th inj.: p = 0.001), reaching similar 
values as s.c. IFA immunized control groups (1st inj.: 3.113 ± 0.19cells/mm², 4th inj.:4.88 
± 0.58cells/mm²). S.c. MOG immunized animals analyzed at day 3 post lesion induction 
showed significantly increased values when compared to their corresponding s.c. IFA 








Figure 13: Density of activated macrophages/microglia 
Density of activated macrophages was determined on ED1-stained sections. Strong and extensive activation of macrophages/microglia 
was observed in s.c. MOG immunized animals 3 days post lesion induction. (A) Within the center of lesion in cortical layer III, 
density of ED1-positive cells decreased significantly after four lesion inductions compared to previous ones. (B) Quantification of 
ED1-positive cells performed in a wider cortical lesional area (ranging from layer I-V) revealed significantly decreased cell counts 
already after two lesion inductions. Twenty-one days after each lesion induction, inflammation resolved as only few ED1-positive 
cells were detected (A and B). S.c. IFA immunized controls showed negligible numbers of ED1-positive cells (A and B). Data are 
expressed as mean + SEM. For statistical evaluation, one-way ANOVA followed by post-hoc LSD-test was performed (* = p < 0.05, 





3.5 Axonal integrity 
To analyse putative degenerative effects on axons, Bielschowsky silver stained sections 
were analysed in cortical layer III at the center of lesion. Bielschowsky silver staining 
showed no substantial alterations of axonal morphology, except in areas immediately 
adjacent to the injection site due to surgical minitrauma (Figure 14). Quantitative analysis 
revealed constant levels in axonal density in s.c. MOG immunized animals (Figure 15, 1st 
inj.: 92.16 ± 9.48%, 2nd inj.: 112.0 ± 14.27%, 4th inj.: 90.33 ± 12.91%) and s.c. IFA 
immunized control animals (1st inj.: 96.68 ± 7.95%, 4th inj.: 116.0 ± 19.27%) at day 3 
after lesion induction. No significant differences were detected. These results show that 
























Representative photographs of Bielschowsky silver-stained sections of cortical layer 3 (center of lesion). The different immunization 
protocols (s.c. MOG and s.c. IFA) are arranged in columns. The different numbers of lesion inductions (1st, 2nd and 4th) are arranged in 
rows. Axonal distribution appeared normal in s.c. MOG and s.c. IFA immunized control animals. 
Scale bars: 20µm 
 
Figure 15: Axonal density 
Axonal density was determined on Bielschowsky silver-stained sections. No alterations in axonal density were detected within center 
of lesion in cortical layer III. Data are expressed as mean + SEM.  
3.6 Oligodendrocyte loss and recovery 
To determine an effect of demyelination and subsequent remyelination on 
oligodendrocyte population, immunohistochemistry was performed using NogoA as a 
marker for mature oligodendrocytes. 
Three days after intracerebral cytokine injection, substantial loss of oligodendrocytes was 
observed within demyelinated cortical lesions of s.c. MOG immunized animals. 
Oligodendroglial loss was most obvious within the center of intracortical lesions of 
several animals (Figure 16). Furthermore, a reduction of oligodendrocyte densities was 
also evident in demyelinated subpial areas after single and repeated lesioning (Figure 17). 
Following remyelination at 21 after lesion induction, the oligodendrocyte population was 

















Figure 16: Loss of oligodendrocytes during focal cortical inflammatory demyelination 
Representative photographs of a NogoA/MBP double-immunostained section of a cortical lesion. In normal appearing gray matter 
(MBP-positive myelin sheaths = red) numerous oligodendrocytes (indicated by arrows) were observed (A, B and C).  Demyelination 
(lesion border is indicated by dotted line) was accompanied by loss of oligodendrocytes (A, D and E).  
Scale bars: A= 100µm, B-E = 20µm 
3.6.1 Oligodendrocyte density 
Quantitative analysis of oligodendrocyte density in subpial lesions revealed significant 
differences between analysed groups (Figure 18, one-way ANOVA F8,51= 4,041, p = 
0.001). At day 3 after singly induced lesion in s.c. MOG immunized animals, post-hoc 
LSD-test revealed decreased oligodendrocyte density (4.91 ± 1.54cells/mm²) compared to 
remyelinated animals (16.27 ± 3.59cells/mm², p = 0.004), s.c. IFA controls (1st inj.: 20.77 
± 2.63cells/mm², p= 0.001) and untreated controls (17.89 ± 2.64cells/mm², p = 0.002). 





in oligodendrocyte density at day 3 (11.14 ± 3.04cells/mm²) compared to remyelinated 
animals at day 21 (23.52 ± 3.88cells/mm², post-hoc LSD-test: p = 0.011). After a fourth 
demyelinating episode, oligodendrocyte density was not significantly decreased in day 3 
animals (6.75 ± 2.84cells/mm²) compared to the corresponding remyelinated s.c. MOG 
immunized group at day 21 (11.57 ± 3.0cells/mm²) and the corresponding s.c. IFA 
control group (4th inj.: 16.07 ± 0.8cells/mm²), but was significantly decreased when 




















Figure 17: Spontaneous recovery of oligodendrocytes in subpial lesions 
Representative photographs of NogoA/MBP double immunostained sections of lesioned subpial cortical area. The different time 
points (days 3 and 21) and immunization protocols (s.c. MOG and s.c. IFA) are arranged in columns. The different numbers of lesion 
inductions (1st, 2nd and 4th) are arranged in rows. Loss of oligodendrocytes (brown shaped cells) was observed within subpial lesions at 
day 3 post lesion induction (left column). Twenty-one days after lesion induction, NogoA-positive cell population recovered (middle 
column). NogoA-positive cell population was not affected in s.c. IFA primed controls (right column). 







Figure 18: Density of oligodendrocytes 
Oligodendrocyte density was determined within lesioned subpial cerebral cortex of NogoA/MBP double stained sections. At 3 days 
post lesion induction, NogoA-positive cell density decreased significantly followed by recovery (at day 21) after single and two 
demyelinating events.  At day 3 post fourth lesion induction, loss of oligodendrocytes was only significant when compared to 
untreated controls. Data are expressed as mean + SEM. The mean of the untreated controls is indicated by dotted line. For statistical 
evaluation, one-way ANOVA followed by post-hoc LSD-test was performed (* = p < 0.05, ** = p < 0.01). 
3.6.2 Proliferation of NogoA-positive oligodendrocytes 
To assess the effect of repeated lesion induction on the proliferation of oligodendrocytes, 
NogoA-positive cells were labelled with the proliferation marker BrdU. 
Oligodendrocytes which underwent cell division during BrdU administration were 
detected by NogoA/BrdU double immunohistochemistry (Figure 19). 
At day 21 after single lesioning, few cells double-positive for NogoA and BrdU were 
detected within remyelinated subpial areas of s.c. MOG immunized animals (Figure 20, 
3.87 ± 1.14cells/mm²). NogoA/BrdU-double positive cell density did not differ 
significantly in repetitively injected animals (2nd inj.: 0.57 ± 0.51cells/mm², 4th inj.: 2.34 
± 0.73cells/mm²).  
The proliferation of oligodendrocytes was analysed in more detail in a further 
experiment. Three days post lesion induction (Figure 21), few NogoA/BrdU double-





immunized controls animals (2.87 ± 1.98cells/mm²). At 21 days post lesion induction 
(Figure 22), comparably low densities of NogoA/BrdU double-positive cells were 
detected in s.c. MOG immunized animals (2.30 ± 2.30cells/mm²) and s.c. IFA immunized 
control animals (cytokine injection: 1.16 ± 0.804; PBS injection: 0.78 ± 0.49cells/mm²; 
no injection: 0.35 ± 0.35cells/mm²). No significant differences were detected between the 




















Figure 19: Oligodendrocyte proliferation during remyelination 
Representative photographs of NogoA/BrdU double immunostained sections of subpial lesions. The different numbers of lesion 
inductions (1st, 2nd and 4th) are arranged in rows. Few mature NogoA-labelled oligodendrocytes cells (red) incorporated the 
proliferation marker BrdU (brown), which was administrated at days 2 to 7 post lesion induction.   







Figure 20: Proliferation of NogoA-positive cells after repeated demyelinating events 
Density of proliferated oligodendrocytes within lesioned subpial cerebral cortex was determined on NogoA/BrdU double positive 
stained sections.  Twenty-one days post lesion induction, few NogoA/BrdU double positive cells were detected. No statistical 
differences were observed between singly and repetitively lesioned animals. Data are expressed as mean + SEM.  
 
 
Figure 21: Early effects of lesion induction on proliferation of NogoA-positive cells 
Proliferation of mature oligodendrocytes was determined within lesioned subpial cerebral cortex on NogoA/BrdU double 
immunostained sections. Three days post lesion induction, proliferating NogoA-positive cells were observed in both s.c. MOG and s.c. 







Figure  22: Effect of lesion induction on proliferation of mature oligodendrocytes after remyelination 
Proliferation of mature oligodendrocytes was determined within lesioned subpial cerebral cortex on NogoA/BrdU double 
immunohistochemical sections. Twenty-one days post lesion induction, few proliferated oligodendrocytes were detected. S.c. MOG 
immunized animals did not differ significantly from PBS-injected and non-injected controls. Abbreviations: cyt = cytokines. Data are 
expressed as mean + SEM. 
3.7 Oligodendroglial progenitors 
To investigate the effect of inflammatory demyelination on oligodendroglial progenitor 
population, we performed immunohistochemical staining for olig2 (Figure 23). 
At the peak of demyelination at day three after lesion induction, density of olig2-positive 
cells did not alter in s.c. MOG immunized animals (45.75 ± 2.9cells/mm²). However, at 
day 21 after lesion induction, olig2-positive cell density (60.05 ± 6.21cells/mm²) 
increased significantly (one-way ANOVA F8,48 = 3,045 p=0.007) compared to day 3 
animals (post-hoc LSD-test: p = 0.005), s.c. IFA controls (1st inj.: 40.8 ± 0.97cells/mm², 
post-hoc LSD-test: p = 0.001) and untreated controls (45.69 ±  2.53cells/mm², post-hoc 
LSD-test: p = 0.005). After two demyelinating episodes, cell density was increased in 
both day 3 group (54.14 ± 3.08cells/mm², post-hoc LSD-test: p = 0.041) and day 21 
group (57.69 ± 4.27cells/mm², post-hoc LSD-test: p = 0.014) compared to repetitively 
injected s.c. IFA immunized controls (46.1 ± 5.54cells/mm²). Three days after four 
repetitively induced lesions, olig2-positive cell density (59.9 ± 5.2cells/mm²) was 
increased compared to repetitively injected s.c. IFA immunized controls (46.1 ± 
5.34cells/mm², post-hoc LSD-test: p = 0.02) and untreated controls (45.69 ± 





intracerebral cytokine injection, cell density (49.44 ± 6.24cells/mm²) did not differ 






































Figure 23: Unaltered oligodendroglial progenitor population 
Representative photographs of olig2/PLP double fluorescent sections of the lesioned subpial cerebral cortex. The different time points 
(days 3 and 21) are arranged in columns. Lesion inductions (1st, 2nd and 4th) and immunization protocols (s.c. MOG and s.c. IFA) are 
arranged in rows. Merged overview photographs consist of olig2 (red), PLP (green) and DAPI (blue).  Magnifications of single cells 
show olig2 (red, upper inset), DAPI (blue, middle inset) and merged signals (lower inset). Numbers of olig2-positive cell population 
ons. Abbreviation: .n.d. = not determined. 
cale bar = 50µm, length of enlarged image = 16µm 
 
remained unaltered even after repetitive lesion inducti
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Figure 24: Density of oligodendroglial progenitors 
Oligodendroglial progenitor density was determined within lesioned subpial cerebral cortex of olig2-stained sections. Olig2-positive 
cell density did not decrease at any examined time point, even after repetitive lesioning. Twenty-one days after single lesioning and 3 
days after four demyelinating events, olig2-positive cell density increased significantly. Data are expressed as mean + SEM. Mean of 
untreated controls is indicated by dotted line. For statistical evaluation, one-way ANOVA followed by post-hoc LSD-test was 
erformed (* = p < 0.05, ** = p < 0.01). 
d in subpial lesions of s.c. MOG immunized 
animals at day 21 after lesion induction. 
p
 
3.7.1 Proliferation of oligodendroglial progenitors 
To assess the effect of repeated lesion induction on the proliferation of oligodendrocytes, 
NogoA-positive cells were labelled with the proliferation marker BrdU. 
Oligodendrocytes which underwent cell division during BrdU administration were 
detected by NogoA/BrdU double immunohistochemistry (Figure 19). Cells double 





Olig2/BrdU double-positive cells were detected within the subpial cortical lesions (Figure 
25). Constant values were measured after one (12.32 ± 2.65cells/mm²), two (8.78 ± 
2.08cells/mm²) and four (8.57 ± 1.84cells/mm²) demyelinating events (Figure 26). 
In a further experiment, the proliferation of oligodendroglial cells was analysed in more 
detail. Three days post lesion induction (Figure 27), relatively high numbers of 
olig2/BrdU double-positive cells were detected in s.c. MOG immunized (23.34 ± 
6.69cells/mm²) and IFA immunized controls animals (12.29 ± 2.88). No significant 
differences were detected between both groups. Twenty-one days post lesion induction 
(Figure 28), high numbers of olig2/BrdU double-positive cells were detected in s.c. MOG 
immunized animals (15.83 ± 2.06), which were significantly increased (one-way 
ANOVA F3,2 2= 6,594, p = 0.003) compared to all s.c. IFA immunized control groups 
(cytokine injection: 9.94 ± 1.23cells/mm², p = 0.048; PBS injection: 7.70 ± 
2.63cells/mm², p = 0.007; no injection: 4.34 ± 1.12cells/mm², p < 0.001). Within the 
control groups, no statistical differences were observed, but there was a trend for increase 
between non-injected animals and those which received an intracebral cytokine injection 
(p = 0.06). These experiments showed an increased proliferation of OPCs upon 























Figure 25: Proliferation of olig2-positive OPCs within subpial lesions 
Representative photographs of olig2/BrdU double fluorescent sections of the lesioned subpial cerebral cortex. The different time 
points (days 3 and 21) are arranged in columns. Lesion inductions (1st, 2nd and 4th) and immunization protocols (s.c. MOG and s.c. 





single cells show olig2 (red, upper inset), BrdU (green, middle inset) and merged signals (incl. DAPI, lower inset). Substantial 
proliferation of olig2-positive cells was observed at days 3 and 21 after lesion induction. Abbreviation: .n.d. = not determined. 




Figure 26: OPC proliferation after repeated demyelinating events 
Proliferated oligodendroglial progenitor population was determined within lesioned subpial cerebral cortex by olig2/BrdU double 
immunofluorescence. Twenty-one days post lesion induction, moderate density of Olig2/BrdU double-positive cells was detected. 
Values did not differ significantly after repetitive lesion induction. Data are expressed as mean + SEM. 
 
 
Figure 27: Early effects of lesion induction on OPC proliferation 
Proliferation of the oligodendroglial progenitor population was determined within lesioned subpial cerebral cortex by olig2/BrdU 
double immunofluorescence. At 3 days post lesion induction, substantial proliferation of olig2-positive cells was observed in both s.c. 







Figure 28: Effects of lesion induction on OPC proliferation after remyelination 
Proliferation of the oligodendroglial progenitor population was determined within lesioned subpial cerebral cortex by olig2/BrdU 
double immunofluorescence. Twenty-one days post lesion induction, Olig2/brdU double-positive cell density was significantly 
increased compared to the s.c. IFA control groups. Abbreviations: cyt = cytokines. Data are expressed as mean + SEM. For statistical 







In the presented study I investigated the impact of repeated cortical demyelination on the 
intrinsic remyelination capacity. 
Histological analysis revealed widespread subpial and intracortical demyelinated lesions 
within the injected cortical hemisphere. Demyelination was accompanied by loss of 
oligodendrocytes and activation of macrophages/microglia but without apparent axonal 
loss. Although the fraction of myelinated axons did not fully recover, an extensive 
remyelination, restored oligodendrocyte population and resolution of inflammation was 
observed even after repeated lesioning. This was accompanied by a proliferative response 
of olig2 and NogoA-positive cell populations that was already observed during 
demyelination.  
 
4.1 Targeted cortical demyelination shares similarities with cortical MS lesions 
The study of cortical pathology in MS and its clinical manifestations, as well as 
underlying mechanisms has been hampered by the lack of suitable animal models. The 
cerebral cortex shows frequent involvement in MS patients. In contrast, in the classical 
rodent EAE model, lesions are mostly confined to the spinal cord but only rarely affected 
the cerebral cortex. Alternatively, injection of gliotoxins e.g. lysolecithin or ethidium 
bromide were used to induce lesions within the brain of rodents (Yajima and Suzuki, 
1979; Hall, 1972). However, these models do not reflect the immunopathological nature 
of MS lesions in the cerebral cortex. Interestingly, the evolvement of cortical EAE lesions 
was observed in the marmoset EAE model. These lesions occurred spontaneously during 
the disease course and highly resemble cortical MS lesion pathology (von Budingen et 
al., 2004; Pomeroy et al., 2005; Merkler et al., 2006; Merkler et al., 2006b).  However, 
experiments with outbread primates show high requirements for infrastructure and animal 
husbandry, that can only be accomplished in highly specialized centers. A further 
limitation in using outbread primates is the unpredictable disease course, making it 





To gain insight into the important aspects of cortical MS, a novel animal model was 
recently developed in our laboratoty that allows for the targeted induction of cortical 
demyelinating lesions (Merkler et al., 2006). Sensitization of rats against MOG resulted 
in a subclinical immune response. In a second step, stereotactic injection of pro-
inflammatory cytokines into a defined area of the animal’s cortex led to cortical 
demyelination that shows considerable similarities to human cortical MS pathology 
(Merkler et al., 2006). Importantly, neither subclinical MOG sensitization nor cytokine 
injection alone can cause demyelination or important cellular inflammation in the CNS. 
As described in the previous study, we could detect predominantly subpial but also 
intracortical lesions in the targeted EAE model that were reminiscent of cortical lesion 
type II and III described in MS patients (Peterson et al. 2001). This lesion topology 
remained consistent over repeated cycles of de- and re-myelination. Furthermore, cellular 
composition of inflammatory infiltrates matched the observation of cortical MS lesions. It 
is possible that the observed topology may be caused by the distribution of injected 
cytokines in our model. After having been targeted to the deeper cortical layers, the 
injected cytokines are likely to partially drain back to the subpial surface. Thereby, the 
BBB may predominantly be affected in these areas resulting in transient BBB breakdown 
and/or upregulation of adhesion molecules on endothelial cells (Yusuf-Makagiansar et 
al., 2002). In a setting of previous priming against MOG, it is conceivable that 
demyelinating anti-MOG autoantibodies cross the altered BBB as a consequence of 
cytokine injection and subsequently trigger a localized inflammatory response within the 
affected areas. An alternative hypothesis for the observed lesion distribution would be 
that macrophages accumulate preferentially at the meningeal area of cytokine injection 
and thereby secrete demyelinating inflammatory cytokines into the subpial cortical area 
(Serafini et al., 2007). However, this latter scenario is rather unlikely in our model, since 
IFA immunized animals did not reveal signs of demyelination despite the fact that these 
animals showed a certain accumulation of macrophages in the meningeal areas following 
cytokine injection (data not shown). Furthermore, recent findings in MS showed that 
meningeal inflammation seems not to be associated with cortical demyelination (Geurts 






4.2 Effect of repeated demyelinating lesions on remyelination 
Cortical remyelination is a frequent and important repair mechanism in MS (Patani et al., 
2007; Patrikios et al., 2006). The cerebral cortex showed a more extensive remyelinating 
capacity as compared to white matter MS lesions (Albert et al., 2007). Nevertheless, the 
number of chronic demyelinated plaques in the cerebral cortex increases with ongoing 
disease progression (Peterson et al., 2001; Bo et al., 2003; Patani et al., 2007; 
Goldschmidt et al., 2009; Gilmore et al.,  2009; Bo, 2009). Therefore, the objective of 
this study was to investigate the effect of repetitive inflammatory demyelination on the 
endogenous cortical remyelination capacity.  
Although cortical lesions were repeatedly induced in our study, animals revealed 
extensive and in some cases nearly complete remyelination, even after four 
demyelinating episodes. Our results are in line with a previous study which proved 
successful myelin restoration after repeated cycles of ethidium bromide-induced 
demyelination (Penderis et al., 2003). Together, these results suggest at first glance that 
remyelination failure - as can be observed in chronic MS cases - might not solely be the 
result of repetitive demyelinating episodes and further suggest that there are still other 
unknown mediators that may contribute to this phenomenon. Clearly, our study can 
nevertheless not exclude that four cycles of of de- and re-myelination may just not be 
enough to exhaust the intrinsic remyelinating capacity of the cerebral cortex, and that 
remyelination failure in MS may reflect the final consequence of a multitude of such 
events that was not sufficiently recreated by our repeated lesioning approach. One may 
therefore speculate that the targeted cortical EAE lesions reflect the early relapsing-
remitting disease course of MS, in which chronic cortical demyelination is less 
pronounced (Stadelmann et al., 2008). Furthermore, possible differences in the intrinsic 
properties of remyelinating oligodendrocytes in humans and rodents may account for 
these observations. 
As a further parameter of remyelination, we determined the fraction of myelinated fibres 
in the remyelinated cortex. This analysis revealed a reduced fraction of remyelinated 
fibres three weeks after lesioning. To exclude that this change might be explained by still 





analysis five weeks after demyelination (data not shown). However, the fraction of 
remyelinating fibres remained reduced even at this later time point as compared to age-
matched controls. Thus, this data indicates that the process of remyelination was almost 
already complete three weeks after lesion induction. These results indicate that although 
remyelination is extensive, the restoration of myelin content in the cortex is incomplete, 
therefore as expected not equating to normal developmental myelination (Lazzarini, 
2004). The limitations of remyelination are obvious in the ultrastructure of myelin, 
showing reduced myelin sheath thickness and internode length (Perier and Grégoire, 
1965; Blakemore, 1974; Merkler et al., 2006).    
 
4.3 Inflammation in repeated targeted cortical EAE lesions  
In accordance to a previous report demyelination was accompanied by inflammation 
which resolved within three weeks after each lesion induction (Merkler et al., 2006). The 
initial inflammatory response measured by the density of activated 
macrophages/microglia was markedly stronger compared to the subsequent episodes. 
Macrophage/microglia activation might be related to myelin content, as the fraction of 
myelinated axons was also higher before demyelination when compared to remyelination 
time points. However, this seemed not related to lesion size as the extent of 
demyelination did not alter after repetated lesions. The relationship between myelin 
content and inflammation becomes clear when comparing myelin rich white matter 
lesions, which present with strong inflammation, to grey matter lesions, which present 
with relatively little myelin and reduced inflammation (Kerschensteiner et al., 2004: 
Merkler et al., 2006; Peterson et al., 2001; Bo et al., 2003). However, the different local 
environment of white and grey matter could influence the inflammatory response within a 
given lesion. Anti-MOG autoantibody titres were consistently high over time and 
therefore are not the cause for the observed alterations in inflammatory response. 
Speculatively, excessive blood born monocytes were recruited into the area of 
inflammation during the initial demyelinating lesion. Why the repeated inflammatory 





which are abundant in the cerebral cortex could have damped the activation of microglia 
as proposed by Biber and colleagues (Biber et al., 2007).  
The inflammatory process causes tissue damage in EAE and MS. For instance, pro-
inflammatory cytokines such as TNF-α, IFN-γ, interleukin-1 β (IL-1β) and IL-2 have 
been shown to promote oligondendrocyte death in vitro (Selmaj and Raine, 1988; 
Vartanian et al., 1995; Curatolo et al., 1997; Hisahara et al., 1997; Jurewicz et al., 2005). 
Apoptosis-inducing factor-positive oligodendrocyte nuclei were detected around MS 
plaques, suggesting this pathway may contribute to oligodendrocyte loss and disease 
progression (Jurewicz et al., 2005). Furthermore, macrophages and microglia are 
activated by pro-inflammatory cytokines which promote apoptosis of oligodendrocytes 
through oxidative stress or via activation of transcription factor p53 (Merill and Scolding, 
1999; Eizenberg et al., 1995; Ladiwala et al., 1999; Wosik et al., 2003). However, the 
cytokine concentrations used in our model are not cytotoxic, as no effects were observed 
in IFA-immunized control animals.    
 
4.4 Preserved axonal intregrity after repetitive demyelination 
Repetitive lesion induction did not lead to substantial axonal loss. This goes in line with a 
previous study by Merkler and colleagues (Merkler et al., 2006) which reported preserved 
axonal integrity and minimal neuronal death in the targeted cortical EAE model. 
Furthermore, they showed transient accumulation of amyloid precursor protein (APP)-
positive spheroids, correlating with inflammation. Acute axonal damage and minimal 
neuronal loss is also to be assumed in our repetitive lesioning approach, but apparently 
without any cumulating harming effects, as no axonal loss was detected. The fast 
resolution of inflammation in targeted cortical EAE lesions possibly prevented further 
axonal damage. This is supported by several studies suggesting a relationship between the 
extent of axonal damage and the severity of the inflammatory process in EAE and MS 
(Mancardi et al., 2001, Shrivel and Dittel, 2006; Rasmussen et al., 2007; Lassmann et al., 
2001). However, transected neurites and apoptotic neurons were observed in cortical MS 





might have supported axonal preservation as reported by previous studies (Kornek et al., 
2000; Irvine and Blakemore, 2008; Trapp and Nave, 2008).  
 
4.5 Oligodendrocyte recruitment in the targeted cortical EAE model 
Histological assessment revealed normal olig2-positive cells density within the subpial 
cerebral cortex which did not decrease even after repeated cycles of demyelination. The 
cell density even increased at particular time points after lesion induction. This can be 
explained by the fast proliferative response of oligodendroglial cells observed within 
demyelinated areas. From this proliferative population the majority were olig2-positive 
OPCs and only few NogoA-positive cells. This leads to the assumption that the restored 
oligodendrocyte population in the remyelinated cortex, did not derive from proliferated 
OPCs. More likely, oligodendrocytes were preferentially recruited from the local pool of 
abundant OPCs which already persisted before the demylinating lesion was induced 
(Dawson et al., 2003, Levine et al., 2001). One can further speculate that the proliferated 
olig2-positive OPCs might restore the pool of quiescent adult oligodendroglial population 
to replace those which have differentiated into remyelinating oligodendrocytes. This 
seems plausible as, differentiation of OPCs offers a repair mechanism which is fast when 
compared to the longer process required during proliferation and subsequent maturation. 
Moreover, it allows for oligodendrocyte restoration and extensive remyelination within 
21 days. However, both proliferation and differentiation are important mechanisms of 
oligodendrocyte recruitment and which of both mechanisms finally fail in MS is a 
controversial issue. Numerous studies reported OPC recruitment in MS lesions (Prineas 
et al., 1989; Schonrock et al., 1998; Scolding et al., 1998; Chang et al, 2000; Maeda et 
al., 2001). This is supported by experimental demyelination studies underlining the 
potential of OPC recruitment (Carrol and Jennings, 1994; Penderis et al., 2003; Fancy et 
al., 2004; Levine and Reynolds, 1999; Sim et al., 2002). Despite OPC numbers 
decreasing with disease progression, they remain within the lesion, however are 
unresponsive, which therefore indicates a differentiation failure of oligodendroglial 
progenitor cells as the major determinant of remyelination failure in chronic MS 





PDGF-α transgenic animals, where elevated OPC numbers did not improve remyelination 
after chemical demyelination (Woodruff et al., 2004). Nevertheless, the likelihood of 
OPC recruitment failure can not be excluded since OPC depletion may occur after a 
single demyelinating event (Keirstead et al., 1998). This effect is more obvious after 
protracted and sustained exposure to a demyelinating stimulus (Linington et al., 1992; 
Ludwin, 1980). However, in our experimental setting we could not detect a reduction of 
OPC in the demyelinated cortex. This can be explained by the fact that MOG EAE is not 
directed against OPCs since these cells do not express the MOG antigen. 
The density of proliferated OPCs appeared higher at day three after lesion induction than 
after 21 days. A reason for this may be the excessive recruitment of OPCs undergoing 
apoptosis as reported in a previous study (Calver et al., 1998). In addition, this observed 
process can be partly explained by the normal turn over of OPCs, as Olig2 and NG2-
positive cells are the major cycle related cell population in the CNS (Dawson et al., 2000; 
Levine et al., 2001; Geha et al., 2009; Dimou et al., 2008; Zhu et al., 2008).  
Not all OPCs within the cerebral cortex do differentiate to myelinating/remyelinating 
oligodendrocytes (Franklin and ffrench-Constant 2008). Several studies present evidence 
that different OPC subpopulations with different functions such as synaptic transmission 
may exist (Karadottir et al., 2008; Jacobs et al., 2005). This may be achieved by 
glutamate and N-methyl D-aspartate (NMDA) receptors which have been shown to be 
expressed on oligodendroglial membranes (Bergles et al., 2000; Karadottir et al., 2005; 
Kukley et al., 2007). The putative existence of further OPC subpopulations could explain 
why a substantial number of quiescent OPC remain in high numbers in the normal 
cerebral cortex (Dawson et al., 2003, Levine et al., 2001). Another supporting reason is 
that OPC subpopulations derived from OPCs responded differentially to trophic factors 
such as PDGF-AA, FGF-2 and IGF-1 (Mason et al., 2002). Furthermore, competing 
waves of embryonic oligodendrocyte lineages during development support the existence 
of two different oligodendroglial populations (Kessaris et al., 2006). Whether 
aforementioned cells are also present in the brain of the Lewis rat and whether these cells 





NogoA is considered a reliable marker for adult mature oligodendrocytes (Kuhlmann et 
al., 2007). However, during the transition from OPCs to remyelinating oligodendrocytes, 
some cells may express both olig2 and NogoA. Nevertheless, the proportion of wrong 
positive cells might be small. In all probability, the restored population of NogoA-
positive oligodendrocytes contributed to remyelination. However, the presence of 
remyelinating oligodendrocytes in the targeted EAE model should be confirmed by PLP 
in-situ hybridization and electron microscopy in future experiments. 
 
4.6 The origin of proliferated OPCs 
The origin of proliferated OPCs reported in this study is unknown. However, our data 
indicate that OPCs were locally recruited as substantial numbers of proliferated OPCs 
were already observed within demyelinated areas at day three after lesion induction. 
Thus, recruitment from remote brain areas unlikely occurred in such a short time frame. 
Additionally, few OPCs might have migrated from adjacent cortical areas as increased 
numbers of proliferated OPCs were also detected in unaffected cortical areas located 
close to the lesion (data not shown). Furthermore, the subventricular zone (SVZ) is 
discussed in the literature as a potent source for OPCs. The SVZ harbours mitogenic type 
B cells from which OPCs but also astrocytes and neurons derive from this region 
(Levison and Goldman, 1997; Carrol et al., 1998; Menn et al., 2006). These cells migrate 
through the rostral migratory pathway (RMS) to their destination and have been shown to 
be a potential source of oligodendrocyte recruitment in experimental demyelination 
studies (Aguirre et al., 2007; Nait-Oumesmar et al., 1999; Picard-Riera et al., 2002). SVZ 
activation was also described in MS patients (Nait-Oumesmar et al., 2007), although the 
role of SVZ proliferation and migration might play only a minor role in human disease. 
Firstly, the contribution of SVZ-derived cells may be relatively small compared to local 
OPCs, and especially as it occurs in remote places of the brain. Secondly, 
oligodendroglial precursors may be recruited from areas adjacent to demyelinated lesions. 
This is supported by increased oligodendroglial cell counts observed at the rim of MS 
lesions (Raine et al., 1981; Prineas et al., 1989; Robinson et al., 1998).  





4.7 Indications of overstrained remyelination capacity 
Histological evaluation revealed extensive remyelination after repetitive demyelination. 
In addition, oligodendrocyte population recovered at least after the first two 
demyelinating events. However, twenty-one days after the fourth lesion induction 
NogoA-positive cells counts ranged between the values of the demyelinated and control 
groups. Therefore, it is hard to state whether the oligodendrocyte population is fully 
restored or not. Assuming the previous statement, reduced oligodendrocyte number could 
indicate the start of impaired oligodendrocyte recruitment, which is unclear after the 
fourth injection. This may have become more apparent if further lesioning was 
performed. Similarly, exhaustion of the remyelination capacity can be induced after 
protracted and sustained exposure to a demyelinating stimulus, this does not reflect those 
conditions of cortical MS lesions (Linington et al., 1992; Ludwin, 1980).  
Furthermore, one should keep in mind that MS patients may experience many 
demyelinating episodes during the usually long disease course, whereby cortical 
demyelinating lesions can be observed in early disease stages (Okuda et al., 2009; Lebrun 
et al., 2008). Moreover, signs of previous demyelination were detected in normal 
appearing grey matter of MS patients (Albert et al., 2007). When considering the number 
of undetected and obvious lesions that MS patients suffer throughout disease, loss of 
remyelination capacity due to frequent demyelinating episodes still provides a possible 
explanation for chronic demyelinated plaques. 
 
4.8 Role of reactive astrocytes on remyelination 
Moderate astrogliosis was observed in close proximity to the needle track. In 
concordance to our results, cortical MS lesions present with moderate astrogliosis 
compared to white matter lesions (Stadelmann et al., 2008). The role of astrocytes on de- 
and re-myelination is not fully understood. On the one hand astrocyte-derived hyaluronan 
seem to inhibit OPC maturation and thereby may contribute to the chronicity of plaques 
(Back et al., 2005). On the other hand astrocytes may also be beneficial as they secrete 
the neuroprotective ciliary neurotrophic factor (Albrecht et al., 2007). Furthermore, lack 





which indicates an important role of these cells on remyelination (Talbott et al., 2005). 
However, aforementioned effects may play a minor role in our model, since astrogliosis 
observed in our study is negligible.  
 
4.9 Hormonal effects on targeted cortical EAE  
For induction of targeted EAE lesions female Lewis rats were used. To analyse whether 
disturbances in estrous cycle may interfere with the outcome of our experiments, the 
estrous cycle was determined in a subgroup of animals. Preliminary results indicate a 
transient disturbance of the estrous cycle in the targeted cortical EAE model (Appendix, 
Figure A). Whether a disturbed estrous cycle might interfere with remyelination and 
oligodendrocyte recruitment needs to be analysed in more detail. However, sex hormonal 
alterations play a role in MS, as some patients experience an alleviation of symptoms 
during the third trimester of pregnancy which may be related to high levels of estrogen 
(Confavreux et al., 1998). Furthermore, 17-β-estradiol and estriol promoted 
immunosuppression was confirmed in EAE experiments (Confavreaux et al., 1998; 
Voskuhl, 2002; Kim et al., 1999; Bebo et al., 2001; Ito et al. 2001). In contrast, hormonal 
fluctuations in menstrual cycle or menopause seems to be associated with exacerbations 
of MS symptoms, however definite conclusions are missing due to technical limitations 
and conflicting results (Smith and Studd, 1992; Nicot, 2009).  
Stress is linked to hormonal changes and may thereby influence the disease course in 
autoimmune human diseases and animal models (Heesen et al., 2007; Morale et al., 2001; 
Foster et al., 2003; Kalantaridou et al., 2004; Herzog et al., 2009). Ovariectomies can be 
performed to reduce sex hormone related interferences in animal experiments, as for 
instance estrogen promoted neuroprotection (Hoffman et al., 2001; Offner et al., 2006; 
Morales et al., 2006). However, changes in estrous cycle related hormonal function may 
possibly occur in our model, although it is likely not do not to have a strong impact on the 











This work demonstrates the extensive intrinsic regenerative capacity of the rat cerebral 
cortex after repeated demyelinating insult. Four cycles of cortical demyelinating episodes 
did not lead to reduction of the cortical remyelinating capacity in our experimental 
setting. Our results suggest furthermore that oligodendroglial recruitment occurs by 
differentiation of existing rather than newly generated OPCs within the cerebral cortex. 
Findings from these studies will contribute to understanding the underlying processes of 
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Figure A: Effect of targeted cortical EAE on estrous cycle 
The effect of targeted cortical EAE on the estrous cycle was analyzed. Daily vaginal smears were collected 
and values are given as percentage of rats having regular estrous cycle each week. Two weeks post lesion 
induction a transient disruption of the estrous cycle was observed in some s.c. MOG immunized animals. 
The phases of estrous cycle were determined using standard criteria as described by Herzog and colleagues 
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